[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLncSj7WrwoV_TYU5X56uEee_WK5DXHEU0psEOcXAtZk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Insel Gruppe AG, University Hospital Bern",[4],728,false,179,25,1440652,50,557,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Coronary Artery Disease",30,{"name":18,"count":19},"Anesthesia",14,{"name":21,"count":22},"Stroke",11,{"name":24,"count":25},"Pain",10,{"name":27,"count":25},"Atrial Fibrillation",{"name":29,"count":25},"Ischemic Stroke",{"name":31,"count":32},"Aortic Valve Stenosis",8,{"name":34,"count":32},"Healthy",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04704986","Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomatic Paroxysmal AF","2023-07-31","PVI using the PolarX Cryoballoon",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06951802","Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine","2025-06-30","Ketamine",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06330584","Administration of Intranasal Midazolam for Anxiety in Palliative Care","2025-09","Midazolam Nasal Spray 0.45 mg\u002Fspray",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06333275","Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","2025-12","Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06128330","Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery","2025-12-31","Tranexamic acid bolus 20 mg\u002Fkg",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07434713","EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","2026-03-27","treatment with Aflibercept 8mg",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06556446","Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants","2026-03-31","Tenecteplase and Alteplase",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04874428","Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","2026-06","Rivaroxaban 10 mg Oral",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04873583","High Dose Steroids in Children With Stroke","2026-07","Methylprednisolone",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06497894","No More Sleepless Nights in Perimenopause","2026-07-01","Hormone Replacement Therapy",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,139,189,218,244,262,280,305,336,363,381,404,422,445,469,487,505,523,549,571,589,614,651,669,694,712,730,756,781,799,824,842,871,889,914,956,974,1027,1061,1081,1110,1128,1155,1179,1205,1225,1249,1270,1295,1313,1331,1396,1455,1490,1512,1538,1566,1584,1609,1636,1663,1681,1709,1727,1745,1770,1794,1822,1840,1858,1876,1903,1921,1946,1964,1995,2013,2040,2058,2083,2101,2119,2137,2161,2185,2209,2233,2258,2283,2301,2319,2346,2372,2406,2428,2467,2494,2512,2530,2554,2581,2599,2625,2651,2675,2699,2724,2742,2768,2786,2804,2828,2853,2878,2924,2959,2981,3017,3054,3077,3101,3128,3146,3172,3190,3219,3246,3264,3282,3306,3324,3347,3371,3394,3412,3437,3455,3479,3503,3521,3546,3564,3582,3600,3618,3643,3667,3685,3711,3734,3752,3775,3799,3823,3848,3866,3891,3928,3950,3968,3986,4004,4022,4040,4058,4081,4106,4131,4149,4176,4194,4221,4284,4323,4359,4391,4425,4447,4469,4494,4519,4543,4566,4594,4612,4630,4648,4666,4692,4719,4737,4755,4781,4809,4834,4861,4879,4897,4915,4942,4960,4986,5009,5032,5060,5078,5103,5128,5153,5176,5198,5225,5243,5261,5279,5304,5322,5350,5374,5397,5415,5441],{"intervention":95,"totalTrials":96,"cells":97},"DOAC",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":127},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":126,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":123},"NCT05955365","Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","RECRUITING",[91],"2027-12-31","2028-06-30","2023-12-18",3010,[119,120,121,122],"Percutaneous Coronary Intervention (PCI)","Atrial Fibrillation (AF)","Oral Anticoagulation","P2Y12 Inhibitor",[124,125,95],"P2Y12 inhibitor","Aspirin",1,{"trials":128,"activeCount":126,"soonestReadout":133},[129],{"nctId":130,"briefTitle":131,"status":112,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT05976685","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy",[92],"2028-01-01","2028-06-01","2024-05-01",482,[29,27],[95],{"intervention":140,"totalTrials":141,"cells":142},"Propofol",3,{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":187},{"trials":144,"activeCount":100},[],{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":100},[],{"trials":152,"activeCount":126,"soonestReadout":44},[153,166,179],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":165},"NCT03844841","The Deep Sedation for Ablation Study","COMPLETED",[91],"2020-12-31","2019-07-01",160,[27,162,163,140,164],"Ablation","Sedation","Dexmedetomidine",[140,164],{"nctId":167,"briefTitle":168,"status":156,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT00415701","Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery",[91],"2009-12","2006-11",130,[15,174],"Mitral Valve Regurgitation",[176,140,177,178],"Etomidate","Hydrocortisone","NaCl 0.9%",{"nctId":42,"briefTitle":43,"status":112,"phases":180,"primaryCompletion":44,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},[91],"2026-12-31","2024-12-03",118,[185],"Endometriosis",[45,140],{"trials":188,"activeCount":100},[],{"intervention":190,"totalTrials":126,"cells":191},"DOR\u002FDTG\u002F3TC",{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":216},{"trials":193,"activeCount":100},[],{"trials":195,"activeCount":100},[],{"trials":197,"activeCount":100},[],{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":126,"soonestReadout":207},[202],{"nctId":203,"briefTitle":204,"status":205,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":215},"NCT06037564","B-free Multistage Trial","ENROLLING_BY_INVITATION",[91],"2026-10","2027-09","2023-11-13",210,[212,213,214],"HIV","Drug Resistance","Drug Drug Interaction",[190],{"trials":217,"activeCount":100},[],{"intervention":219,"totalTrials":126,"cells":220},"dexmedetomidine to the standard treatment",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":242},{"trials":222,"activeCount":100},[],{"trials":224,"activeCount":100},[],{"trials":226,"activeCount":100},[],{"trials":228,"activeCount":100},[],{"trials":230,"activeCount":126,"soonestReadout":236},[231],{"nctId":232,"briefTitle":233,"status":234,"phases":235,"primaryCompletion":236,"completion":237,"start":236,"enrollment":238,"conditions":239,"interventions":241},"NCT07597109","Effect of Dexmedetomidine on Hemodynamic Stability in Carotid Endarterectomy: Reduced Norepinephrine Use and Propofol Dosing Via Central Sympatholytic Action","NOT_YET_RECRUITING",[91],"2026-09-01","2028-09-30",44,[240],"Steno-occlusive Disease",[219],{"trials":243,"activeCount":100},[],{"intervention":124,"totalTrials":126,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":260},{"trials":247,"activeCount":100},[],{"trials":249,"activeCount":100},[],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":126,"soonestReadout":114},[256],{"nctId":110,"briefTitle":111,"status":112,"phases":257,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":258,"interventions":259},[91],[119,120,121,122],[124,125,95],{"trials":261,"activeCount":100},[],{"intervention":125,"totalTrials":126,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":278},{"trials":265,"activeCount":100},[],{"trials":267,"activeCount":100},[],{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":126,"soonestReadout":114},[274],{"nctId":110,"briefTitle":111,"status":112,"phases":275,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":276,"interventions":277},[91],[119,120,121,122],[124,125,95],{"trials":279,"activeCount":100},[],{"intervention":281,"totalTrials":126,"cells":282},"Tenecteplase or Alteplase",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":303},{"trials":284,"activeCount":100},[],{"trials":286,"activeCount":100},[],{"trials":288,"activeCount":100},[],{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":126,"soonestReadout":297},[293],{"nctId":294,"briefTitle":295,"status":112,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":302},"NCT06571149","Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake",[91],"2029-01-31","2029-04-30","2025-03-14",906,[29],[281],{"trials":304,"activeCount":100},[],{"intervention":306,"totalTrials":126,"cells":307},"Landiolol",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":334},{"trials":309,"activeCount":100},[],{"trials":311,"activeCount":100},[],{"trials":313,"activeCount":100},[],{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":126,"soonestReadout":322},[318],{"nctId":319,"briefTitle":320,"status":112,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":333},"NCT07168421","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery",[91],"2028-01-31","2028-03-01","2026-04-24",114,[327,328,329,330,331,332],"Perioperative Myocardial Injury","Autonomic Dysfunction","Cardiovascular (CV) Risk","Major Surgery","Beta Blocker","Myocardial Injury After Non-cardiac Surgery",[306],{"trials":335,"activeCount":100},[],{"intervention":337,"totalTrials":126,"cells":338},"Gadobutrol",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":361},{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":126,"soonestReadout":353},[349],{"nctId":350,"briefTitle":351,"status":112,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT07040865","Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings",[91],"2027-06-30","2027-07-31","2025-08-18",104,[358],"Suspect Renal and Adrenal Imaging Findings",[337,360],"Gadopiclenol",{"trials":362,"activeCount":100},[],{"intervention":360,"totalTrials":126,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":379},{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"trials":370,"activeCount":100},[],{"trials":372,"activeCount":100},[],{"trials":374,"activeCount":126,"soonestReadout":353},[375],{"nctId":350,"briefTitle":351,"status":112,"phases":376,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":377,"interventions":378},[91],[358],[337,360],{"trials":380,"activeCount":100},[],{"intervention":85,"totalTrials":126,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":402},{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[],{"trials":392,"activeCount":126,"soonestReadout":84},[393],{"nctId":82,"briefTitle":83,"status":112,"phases":394,"primaryCompletion":84,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":401},[91],"2027-01-30","2026-01-01",54,[399,400],"Insomnia","Menopause",[85],{"trials":403,"activeCount":100},[],{"intervention":45,"totalTrials":126,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":420},{"trials":407,"activeCount":100},[],{"trials":409,"activeCount":100},[],{"trials":411,"activeCount":100},[],{"trials":413,"activeCount":100},[],{"trials":415,"activeCount":126,"soonestReadout":44},[416],{"nctId":42,"briefTitle":43,"status":112,"phases":417,"primaryCompletion":44,"completion":181,"start":182,"enrollment":183,"conditions":418,"interventions":419},[91],[185],[45,140],{"trials":421,"activeCount":100},[],{"intervention":40,"totalTrials":126,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":443},{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":100},[],{"trials":429,"activeCount":100},[],{"trials":431,"activeCount":100},[],{"trials":433,"activeCount":126,"soonestReadout":39},[434],{"nctId":37,"briefTitle":38,"status":435,"phases":436,"primaryCompletion":39,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},"ACTIVE_NOT_RECRUITING",[91],"2025-07-31","2021-03-29",201,[441],"Paroxysmal Atrial Fibrillation",[40],{"trials":444,"activeCount":100},[],{"intervention":60,"totalTrials":126,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":467},{"trials":448,"activeCount":100},[],{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":100},[],{"trials":456,"activeCount":126,"soonestReadout":59},[457],{"nctId":57,"briefTitle":58,"status":112,"phases":458,"primaryCompletion":59,"completion":181,"start":459,"enrollment":460,"conditions":461,"interventions":463},[91],"2023-12-15",322,[462],"Antifibrinolytic Agents",[60,464,465,466],"Tranexamic acid bolus 10 mg\u002Fkg","Tranexamic acid bolus 1 mg\u002Fkg","Tranexamic acid continuous infusion of 1 mg\u002Fkg\u002Fh in the low dose group",{"trials":468,"activeCount":100},[],{"intervention":464,"totalTrials":126,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":485},{"trials":472,"activeCount":100},[],{"trials":474,"activeCount":100},[],{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":126,"soonestReadout":59},[481],{"nctId":57,"briefTitle":58,"status":112,"phases":482,"primaryCompletion":59,"completion":181,"start":459,"enrollment":460,"conditions":483,"interventions":484},[91],[462],[60,464,465,466],{"trials":486,"activeCount":100},[],{"intervention":465,"totalTrials":126,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":503},{"trials":490,"activeCount":100},[],{"trials":492,"activeCount":100},[],{"trials":494,"activeCount":100},[],{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":126,"soonestReadout":59},[499],{"nctId":57,"briefTitle":58,"status":112,"phases":500,"primaryCompletion":59,"completion":181,"start":459,"enrollment":460,"conditions":501,"interventions":502},[91],[462],[60,464,465,466],{"trials":504,"activeCount":100},[],{"intervention":466,"totalTrials":126,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":521},{"trials":508,"activeCount":100},[],{"trials":510,"activeCount":100},[],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":100},[],{"trials":516,"activeCount":126,"soonestReadout":59},[517],{"nctId":57,"briefTitle":58,"status":112,"phases":518,"primaryCompletion":59,"completion":181,"start":459,"enrollment":460,"conditions":519,"interventions":520},[91],[462],[60,464,465,466],{"trials":522,"activeCount":100},[],{"intervention":524,"totalTrials":126,"cells":525},"Empagliflozin 10 MG",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":545,"NA":547},{"trials":527,"activeCount":100},[],{"trials":529,"activeCount":100},[],{"trials":531,"activeCount":100},[],{"trials":533,"activeCount":126,"soonestReadout":538},[534],{"nctId":535,"briefTitle":536,"status":234,"phases":537,"primaryCompletion":538,"completion":538,"start":74,"enrollment":539,"conditions":540,"interventions":544},"NCT06653738","Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention",[90],"2030-09",400,[541,542,543],"Kidney Stone","Nephrolithiasis","Dietary Exposure",[524],{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":100},[],{"intervention":80,"totalTrials":126,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":567,"NA":569},{"trials":552,"activeCount":100},[],{"trials":554,"activeCount":100},[],{"trials":556,"activeCount":100},[],{"trials":558,"activeCount":126,"soonestReadout":79},[559],{"nctId":77,"briefTitle":78,"status":112,"phases":560,"primaryCompletion":79,"completion":79,"start":561,"enrollment":562,"conditions":563,"interventions":565},[90],"2021-11-16",70,[564],"Paediatric Stroke",[80,566],"Prednisolone",{"trials":568,"activeCount":100},[],{"trials":570,"activeCount":100},[],{"intervention":566,"totalTrials":126,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":585,"NA":587},{"trials":574,"activeCount":100},[],{"trials":576,"activeCount":100},[],{"trials":578,"activeCount":100},[],{"trials":580,"activeCount":126,"soonestReadout":79},[581],{"nctId":77,"briefTitle":78,"status":112,"phases":582,"primaryCompletion":79,"completion":79,"start":561,"enrollment":562,"conditions":583,"interventions":584},[90],[564],[80,566],{"trials":586,"activeCount":100},[],{"trials":588,"activeCount":100},[],{"intervention":590,"totalTrials":126,"cells":591},"Prednisone",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":610,"NA":612},{"trials":593,"activeCount":100},[],{"trials":595,"activeCount":100},[],{"trials":597,"activeCount":100},[],{"trials":599,"activeCount":126,"soonestReadout":604},[600],{"nctId":601,"briefTitle":602,"status":234,"phases":603,"primaryCompletion":604,"completion":605,"start":79,"enrollment":606,"conditions":607,"interventions":609},"NCT06833411","Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone",[90],"2030-08","2032-08",178,[608],"Giant Cell Arteritis (GCA)",[590,590],{"trials":611,"activeCount":100},[],{"trials":613,"activeCount":100},[],{"intervention":615,"totalTrials":96,"cells":616},"Melphalan",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":645,"PHASE4":647,"NA":649},{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":100},[],{"trials":622,"activeCount":126,"soonestReadout":627},[623,635],{"nctId":624,"briefTitle":625,"status":112,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT05636787","Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients",[89],"2028-01","2028-04","2023-06-06",120,[632],"Multiple Myeloma",[634,615],"Treosulfan",{"nctId":636,"briefTitle":637,"status":156,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":630,"conditions":642,"interventions":643},"NCT03187223","Bendamustine and Melphalan in Myeloma",[89],"2020-03-12","2020-05-28","2017-07-20",[632],[615,644],"Bendamustine",{"trials":646,"activeCount":100},[],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":100},[],{"intervention":634,"totalTrials":126,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":654,"activeCount":100},[],{"trials":656,"activeCount":100},[],{"trials":658,"activeCount":126,"soonestReadout":627},[659],{"nctId":624,"briefTitle":625,"status":112,"phases":660,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":661,"interventions":662},[89],[632],[634,615],{"trials":664,"activeCount":100},[],{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"intervention":670,"totalTrials":126,"cells":671},"Indapamide 2.5 MG",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":100},[],{"trials":677,"activeCount":126,"soonestReadout":353},[678],{"nctId":679,"briefTitle":680,"status":112,"phases":681,"primaryCompletion":353,"completion":353,"start":682,"enrollment":683,"conditions":684,"interventions":685},"NCT06111885","Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention",[89],"2024-10-01",99,[541],[670,686,687],"Hydrochlorothiazide 50Mg","Chlorthalidone 25mg",{"trials":689,"activeCount":100},[],{"trials":691,"activeCount":100},[],{"trials":693,"activeCount":100},[],{"intervention":686,"totalTrials":126,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":100},[],{"trials":701,"activeCount":126,"soonestReadout":353},[702],{"nctId":679,"briefTitle":680,"status":112,"phases":703,"primaryCompletion":353,"completion":353,"start":682,"enrollment":683,"conditions":704,"interventions":705},[89],[541],[670,686,687],{"trials":707,"activeCount":100},[],{"trials":709,"activeCount":100},[],{"trials":711,"activeCount":100},[],{"intervention":687,"totalTrials":126,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":715,"activeCount":100},[],{"trials":717,"activeCount":100},[],{"trials":719,"activeCount":126,"soonestReadout":353},[720],{"nctId":679,"briefTitle":680,"status":112,"phases":721,"primaryCompletion":353,"completion":353,"start":682,"enrollment":683,"conditions":722,"interventions":723},[89],[541],[670,686,687],{"trials":725,"activeCount":100},[],{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":100},[],{"intervention":731,"totalTrials":126,"cells":732},"Vancomycin",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":734,"activeCount":100},[],{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":126,"soonestReadout":743},[739],{"nctId":740,"briefTitle":741,"status":435,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":749},"NCT04017468","Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion",[89],"2026-09-30","2027-03-31","2019-10-15",450,[748],"Surgical Site Infection",[731],{"trials":751,"activeCount":100},[],{"trials":753,"activeCount":100},[],{"trials":755,"activeCount":100},[],{"intervention":757,"totalTrials":126,"cells":758},"AzaFol",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":760,"activeCount":100},[],{"trials":762,"activeCount":100},[],{"trials":764,"activeCount":126,"soonestReadout":769},[765],{"nctId":766,"briefTitle":767,"status":112,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":562,"conditions":771,"interventions":773},"NCT06335888","A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis",[89],"2029-05","2025-02-03",[772],"Giant Cell Arteritis",[757,774],"FDG",{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":100},[],{"intervention":774,"totalTrials":126,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":126,"soonestReadout":769},[789],{"nctId":766,"briefTitle":767,"status":112,"phases":790,"primaryCompletion":769,"completion":769,"start":770,"enrollment":562,"conditions":791,"interventions":792},[89],[772],[757,774],{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"intervention":50,"totalTrials":126,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":126,"soonestReadout":49},[807],{"nctId":47,"briefTitle":48,"status":112,"phases":808,"primaryCompletion":49,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":816},[89],"2025-10","2024-12-20",36,[813,814,815],"Anxiety","Acute Anxiety","Palliative Care",[50,817],"Midazolam Nasal Spray 0.9 mg\u002Fspray",{"trials":819,"activeCount":100},[],{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":100},[],{"intervention":817,"totalTrials":126,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":836,"PHASE4":838,"NA":840},{"trials":827,"activeCount":100},[],{"trials":829,"activeCount":100},[],{"trials":831,"activeCount":126,"soonestReadout":49},[832],{"nctId":47,"briefTitle":48,"status":112,"phases":833,"primaryCompletion":49,"completion":809,"start":810,"enrollment":811,"conditions":834,"interventions":835},[89],[813,814,815],[50,817],{"trials":837,"activeCount":100},[],{"trials":839,"activeCount":100},[],{"trials":841,"activeCount":100},[],{"intervention":843,"totalTrials":126,"cells":844},"Tocilizumab before CAR-T cell",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":100},[],{"trials":850,"activeCount":126,"soonestReadout":855},[851],{"nctId":852,"briefTitle":853,"status":112,"phases":854,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":863},"NCT06430736","PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)",[89],"2026-12","2027-06","2024-07-01",100,[860,861,862],"Myeloma","Lymphoma","Leukemia",[843,864],"Tocilizumab at emerging CRS",{"trials":866,"activeCount":100},[],{"trials":868,"activeCount":100},[],{"trials":870,"activeCount":100},[],{"intervention":864,"totalTrials":126,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":874,"activeCount":100},[],{"trials":876,"activeCount":100},[],{"trials":878,"activeCount":126,"soonestReadout":855},[879],{"nctId":852,"briefTitle":853,"status":112,"phases":880,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":881,"interventions":882},[89],[860,861,862],[843,864],{"trials":884,"activeCount":100},[],{"trials":886,"activeCount":100},[],{"trials":888,"activeCount":100},[],{"intervention":890,"totalTrials":126,"cells":891},"Gemcitabin, Cisplatin and Durvalumab",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":893,"activeCount":100},[],{"trials":895,"activeCount":100},[],{"trials":897,"activeCount":126,"soonestReadout":902},[898],{"nctId":899,"briefTitle":900,"status":112,"phases":901,"primaryCompletion":902,"completion":903,"start":904,"enrollment":811,"conditions":905,"interventions":907},"NCT06274879","Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer",[89],"2029-12-30","2030-12-30","2026-05-20",[906],"Bile Duct Cancer",[890],{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":100},[],{"intervention":915,"totalTrials":141,"cells":916},"Rivaroxaban 10 mg",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":948,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":126,"soonestReadout":74},[921,931,939],{"nctId":922,"briefTitle":923,"status":156,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":930},"NCT02438098","Rivaroxaban in Bariatric Surgery",[88],"2015-11","2015-06",13,[929],"Prophylaxis of Venous Thromboembolism",[915],{"nctId":72,"briefTitle":73,"status":112,"phases":932,"primaryCompletion":74,"completion":74,"start":933,"enrollment":934,"conditions":935,"interventions":937},[88],"2021-05-19",24,[936],"Liver Cirrhosis",[75,938],"Apixaban 2.5 mg Oral",{"nctId":940,"briefTitle":941,"status":156,"phases":942,"primaryCompletion":943,"completion":944,"start":945,"enrollment":927,"conditions":946,"interventions":947},"NCT02832947","PK of Rivaroxaban in Bariatric Patients - Extension",[88],"2016-06","2016-10","2016-02",[929],[915],{"trials":949,"activeCount":100},[],{"trials":951,"activeCount":100},[],{"trials":953,"activeCount":100},[],{"trials":955,"activeCount":100},[],{"intervention":938,"totalTrials":126,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":966,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":959,"activeCount":100},[],{"trials":961,"activeCount":126,"soonestReadout":74},[962],{"nctId":72,"briefTitle":73,"status":112,"phases":963,"primaryCompletion":74,"completion":74,"start":933,"enrollment":934,"conditions":964,"interventions":965},[88],[936],[75,938],{"trials":967,"activeCount":100},[],{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[],{"intervention":975,"totalTrials":976,"cells":977},"Oxygen",4,{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[],{"trials":989,"activeCount":126,"soonestReadout":1004},[990,1000,1010,1018],{"nctId":991,"briefTitle":992,"status":156,"phases":993,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":999},"NCT03738722","Positive Airway Pressure Under Apnoeic Oxygenation With Different Flow Rates in Nasal Cannula Therapy",[92],"2019-03-31","2019-01-10",28,[998],"Apnoeic Oxygenation",[975],{"nctId":1001,"briefTitle":1002,"status":112,"phases":1003,"primaryCompletion":1004,"completion":1005,"start":1006,"enrollment":1007,"conditions":1008,"interventions":1009},"NCT04808401","Influence of Oxygen on Perioperative Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery",[92],"2027-12","2028-12","2021-05-07",110,[15,18],[975],{"nctId":1011,"briefTitle":1012,"status":156,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":811,"conditions":1016,"interventions":1017},"NCT02233634","Impact of Breathing Maneuvers on the Oxygenation Supply of the Heart Assessed With MRI in Patients With Coronary Artery Disease",[92],"2017-11-02","2014-10-01",[15],[975],{"nctId":1019,"briefTitle":1020,"status":156,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1026},"NCT04424433","Myocardial Strain Analysis in Anaesthetized Coronary Artery Disease Patients During Hyperoxia and Normoxaemia",[92],"2021-06-04","2020-06-01",106,[15,18],[975],{"intervention":1028,"totalTrials":96,"cells":1029},"Dexamethasone",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1047,"NA":1049},{"trials":1031,"activeCount":100},[],{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"trials":1037,"activeCount":100},[1038],{"nctId":1039,"briefTitle":1040,"status":1041,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":96,"conditions":1045,"interventions":1046},"NCT01311167","Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone","TERMINATED",[90],"2011-11","2011-02",[936],[1028],{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":126,"soonestReadout":1055},[1051],{"nctId":1052,"briefTitle":1053,"status":112,"phases":1054,"primaryCompletion":1055,"completion":628,"start":1056,"enrollment":11,"conditions":1057,"interventions":1060},"NCT04266977","Restrictive Use of Dexamethasone in Glioblastoma",[92],"2027-04","2020-05-08",[1058,1028,1059],"Glioblastoma","Steroids",[1028],{"intervention":65,"totalTrials":126,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1064,"activeCount":100},[],{"trials":1066,"activeCount":100},[],{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"trials":1072,"activeCount":100},[],{"trials":1074,"activeCount":126,"soonestReadout":64},[1075],{"nctId":62,"briefTitle":63,"status":112,"phases":1076,"primaryCompletion":64,"completion":64,"start":1077,"enrollment":11,"conditions":1078,"interventions":1080},[],"2025-07-14",[1079],"Age-Related Macular Degeneration (AMD)",[65],{"intervention":1082,"totalTrials":126,"cells":1083},"0.9% Sodium-chloride",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1085,"activeCount":100},[],{"trials":1087,"activeCount":100},[],{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"trials":1093,"activeCount":100},[],{"trials":1095,"activeCount":126,"soonestReadout":1100},[1096],{"nctId":1097,"briefTitle":1098,"status":112,"phases":1099,"primaryCompletion":1100,"completion":1004,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1108},"NCT04043598","Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage",[92],"2027-07","2022-05-24",320,[1104,1105,1106,1107],"Subarachnoid Hemorrhage","Critical Illness","Infusion Fluid","Sodium Disorder",[1082,1109],"Ringer's Lactate",{"intervention":1109,"totalTrials":126,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":100},[],{"trials":1121,"activeCount":100},[],{"trials":1123,"activeCount":126,"soonestReadout":1100},[1124],{"nctId":1097,"briefTitle":1098,"status":112,"phases":1125,"primaryCompletion":1100,"completion":1004,"start":1101,"enrollment":1102,"conditions":1126,"interventions":1127},[92],[1104,1105,1106,1107],[1082,1109],{"intervention":1129,"totalTrials":126,"cells":1130},"Semaglutide",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[],{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":126,"soonestReadout":181},[1143],{"nctId":1144,"briefTitle":1145,"status":234,"phases":1146,"primaryCompletion":181,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1154},"NCT06546384","GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease",[92],"2027-04-30","2026-05-01",64,[1151,1152,1153],"Adiposity","Fatty Liver","Alcohol Use Disorder",[1129],{"intervention":1156,"totalTrials":126,"cells":1157},"Fremanezumab",{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1168},{"trials":1159,"activeCount":100},[],{"trials":1161,"activeCount":100},[],{"trials":1163,"activeCount":100},[],{"trials":1165,"activeCount":100},[],{"trials":1167,"activeCount":100},[],{"trials":1169,"activeCount":126,"soonestReadout":1174},[1170],{"nctId":1171,"briefTitle":1172,"status":112,"phases":1173,"primaryCompletion":1174,"completion":744,"start":1175,"enrollment":630,"conditions":1176,"interventions":1178},"NCT06659120","Fremanezumab for the Prevention of Menstrually-related Migraine Attacks",[],"2026-12-01","2024-04-09",[1177],"Menstrual Migraine",[1156],{"intervention":1180,"totalTrials":126,"cells":1181},"Metformin treatment",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1183,"activeCount":100},[],{"trials":1185,"activeCount":100},[],{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":126,"soonestReadout":1198},[1194],{"nctId":1195,"briefTitle":1196,"status":234,"phases":1197,"primaryCompletion":1198,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1204},"NCT06762041","Effects of Metformin on Androgens and Other Steroid Hormones in Affected Subjects With Autism",[],"2026-08-30","2026-11-30","2025-01-30",20,[1203],"Autism",[1180],{"intervention":70,"totalTrials":126,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1208,"activeCount":100},[],{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":126,"soonestReadout":69},[1219],{"nctId":67,"briefTitle":68,"status":112,"phases":1220,"primaryCompletion":69,"completion":181,"start":1221,"enrollment":1222,"conditions":1223,"interventions":1224},[],"2024-01-01",2800,[29],[70],{"intervention":1226,"totalTrials":126,"cells":1227},"Androgen deprivation therapy",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1229,"activeCount":100},[],{"trials":1231,"activeCount":100},[],{"trials":1233,"activeCount":100},[],{"trials":1235,"activeCount":100},[],{"trials":1237,"activeCount":100},[],{"trials":1239,"activeCount":126,"soonestReadout":1244},[1240],{"nctId":1241,"briefTitle":1242,"status":435,"phases":1243,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":811,"conditions":1246,"interventions":1248},"NCT05746806","Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy",[92],"2027-11-30","2023-03-29",[1247],"Recurrent Prostate Cancer",[1226],{"intervention":55,"totalTrials":126,"cells":1250},{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1257,"PHASE4":1259,"NA":1261},{"trials":1252,"activeCount":100},[],{"trials":1254,"activeCount":100},[],{"trials":1256,"activeCount":100},[],{"trials":1258,"activeCount":100},[],{"trials":1260,"activeCount":100},[],{"trials":1262,"activeCount":126,"soonestReadout":54},[1263],{"nctId":52,"briefTitle":53,"status":112,"phases":1264,"primaryCompletion":54,"completion":855,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1269},[],"2023-11-14",80,[1268],"Vaccine Immunity in CAR-T Cell Therapy Recipients",[55],{"intervention":1271,"totalTrials":126,"cells":1272},"Botulinum toxin A",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1274,"activeCount":100},[],{"trials":1276,"activeCount":100},[],{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":126,"soonestReadout":855},[1285],{"nctId":1286,"briefTitle":1287,"status":112,"phases":1288,"primaryCompletion":855,"completion":855,"start":1289,"enrollment":397,"conditions":1290,"interventions":1292},"NCT02196155","Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis",[92],"2016-07",[1291],"Plantar Fasciitis",[1271,1293,1294],"cortisone","Saline",{"intervention":1293,"totalTrials":126,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":100},[],{"trials":1302,"activeCount":100},[],{"trials":1304,"activeCount":100},[],{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":126,"soonestReadout":855},[1309],{"nctId":1286,"briefTitle":1287,"status":112,"phases":1310,"primaryCompletion":855,"completion":855,"start":1289,"enrollment":397,"conditions":1311,"interventions":1312},[92],[1291],[1271,1293,1294],{"intervention":1294,"totalTrials":126,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1316,"activeCount":100},[],{"trials":1318,"activeCount":100},[],{"trials":1320,"activeCount":100},[],{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":126,"soonestReadout":855},[1327],{"nctId":1286,"briefTitle":1287,"status":112,"phases":1328,"primaryCompletion":855,"completion":855,"start":1289,"enrollment":397,"conditions":1329,"interventions":1330},[92],[1291],[1271,1293,1294],{"intervention":1332,"totalTrials":1333,"cells":1334},"Levothyroxine",5,{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1343,"NA":1394},{"trials":1336,"activeCount":100},[],{"trials":1338,"activeCount":100},[],{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[],{"trials":1344,"activeCount":100},[1345,1358,1367,1378,1387],{"nctId":1346,"briefTitle":1347,"status":156,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1357},"NCT02491008","Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction",[91],"2016-12","2014-01",145,[1353,1354,1355,1356],"Thyroid Dysfunction","Bone Mineral Density","Osteoporosis","Fractures, Bone",[1332],{"nctId":1359,"briefTitle":1360,"status":156,"phases":1361,"primaryCompletion":1349,"completion":1349,"start":943,"enrollment":1362,"conditions":1363,"interventions":1366},"NCT02832960","The TRUST Trial - CardioVascular Imaging ECHO",[91],185,[1353,1364,1365],"Atherosclerosis","Heart Failure",[1332],{"nctId":1368,"briefTitle":1369,"status":156,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":1373,"conditions":1374,"interventions":1377},"NCT01853579","The TRUST Study - Depression Substudy",[91],"2018-04-05","2013-03",426,[1375,1376],"Subclinical Hypothyroidism","Depression",[1332],{"nctId":1379,"briefTitle":1380,"status":156,"phases":1381,"primaryCompletion":1371,"completion":1371,"start":1350,"enrollment":1382,"conditions":1383,"interventions":1386},"NCT02500342","Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism",[91],276,[1353,1384,1385],"Mental Fatigue","Fatigue",[1332],{"nctId":1388,"briefTitle":1389,"status":156,"phases":1390,"primaryCompletion":1349,"completion":1349,"start":943,"enrollment":1391,"conditions":1392,"interventions":1393},"NCT02832934","The TRUST Study - CardioVascular Imaging IMT",[91],184,[1353,1364,1365],[1332],{"trials":1395,"activeCount":100},[],{"intervention":1397,"totalTrials":976,"cells":1398},"Tolterodine",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1433,"NA":1453},{"trials":1400,"activeCount":100},[],{"trials":1402,"activeCount":100},[],{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[1407,1419],{"nctId":1408,"briefTitle":1409,"status":156,"phases":1410,"primaryCompletion":1411,"completion":1412,"start":170,"enrollment":1413,"conditions":1414,"interventions":1415},"NCT01011036","Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers",[90],"2010-04","2010-06",17,[24],[1416,1417,1418],"clobazam","clonazepam","tolterodine",{"nctId":1420,"briefTitle":1421,"status":156,"phases":1422,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1429},"NCT01179828","Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)",[90],"2015-04","2015-12","2010-07",150,[1428],"Low Back Pain",[1430,1431,1432,1397],"Oxycodone 15mg","Clobazam","Imipramine",{"trials":1434,"activeCount":100},[1435,1447],{"nctId":1436,"briefTitle":1437,"status":156,"phases":1438,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":1442,"conditions":1443,"interventions":1445},"NCT02256956","Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II",[91],"2018-05","2019-01","2014-11",48,[1444],"Chronic Pain",[1446,1397],"Amitriptyline",{"nctId":1448,"briefTitle":1449,"status":156,"phases":1450,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":1442,"conditions":1451,"interventions":1452},"NCT02256943","Genetic Determinants of Amitriptyline Efficiency for Pain Treatment",[91],[1444],[1446,1397],{"trials":1454,"activeCount":100},[],{"intervention":1456,"totalTrials":96,"cells":1457},"Empagliflozin 25 MG",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1473,"PHASE4":1475,"NA":1488},{"trials":1459,"activeCount":100},[],{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[1464],{"nctId":1465,"briefTitle":1466,"status":156,"phases":1467,"primaryCompletion":1468,"completion":1469,"start":1470,"enrollment":11,"conditions":1471,"interventions":1472},"NCT04911660","Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers",[89],"2023-03-30","2023-04-28","2021-08-25",[541],[1456],{"trials":1474,"activeCount":100},[],{"trials":1476,"activeCount":100},[1477],{"nctId":1478,"briefTitle":1479,"status":156,"phases":1480,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1487},"NCT05057819","Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass",[91],"2022-08-11","2021-12-01",22,[1485,1486],"Dumping Syndrome","Hypoglycemia, Reactive",[1456],{"trials":1489,"activeCount":100},[],{"intervention":1446,"totalTrials":96,"cells":1491},{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1510},{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":100},[],{"trials":1499,"activeCount":100},[],{"trials":1501,"activeCount":100},[1502,1506],{"nctId":1436,"briefTitle":1437,"status":156,"phases":1503,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":1442,"conditions":1504,"interventions":1505},[91],[1444],[1446,1397],{"nctId":1448,"briefTitle":1449,"status":156,"phases":1507,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":1442,"conditions":1508,"interventions":1509},[91],[1444],[1446,1397],{"trials":1511,"activeCount":100},[],{"intervention":1513,"totalTrials":126,"cells":1514},"albumin 20%",{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1521,"PHASE4":1523,"NA":1536},{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":100},[1525],{"nctId":1526,"briefTitle":1527,"status":156,"phases":1528,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":934,"conditions":1532,"interventions":1535},"NCT03848507","Impact of Hyperoncotic Albumin to Support Blood Loss Replacement",[91],"2020-02-12","2020-02-18","2019-03-18",[1533,1534],"Blood Loss, Surgical","Fluid Retention",[1513],{"trials":1537,"activeCount":100},[],{"intervention":1539,"totalTrials":126,"cells":1540},"Hypertonic saline",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1564},{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[1551],{"nctId":1552,"briefTitle":1553,"status":156,"phases":1554,"primaryCompletion":1555,"completion":1556,"start":1557,"enrollment":1558,"conditions":1559,"interventions":1562},"NCT03280745","Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery",[91],"2019-05-27","2019-09-30","2018-02-27",165,[1560,1561],"Cardiovascular Diseases","Valvular Heart Disease",[1539,1563],"0.9% saline",{"trials":1565,"activeCount":100},[],{"intervention":1563,"totalTrials":126,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1582},{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[1578],{"nctId":1552,"briefTitle":1553,"status":156,"phases":1579,"primaryCompletion":1555,"completion":1556,"start":1557,"enrollment":1558,"conditions":1580,"interventions":1581},[91],[1560,1561],[1539,1563],{"trials":1583,"activeCount":100},[],{"intervention":1585,"totalTrials":126,"cells":1586},"Utrogestan",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1595,"NA":1607},{"trials":1588,"activeCount":100},[],{"trials":1590,"activeCount":100},[],{"trials":1592,"activeCount":100},[],{"trials":1594,"activeCount":100},[],{"trials":1596,"activeCount":100},[1597],{"nctId":1598,"briefTitle":1599,"status":1041,"phases":1600,"primaryCompletion":1601,"completion":1601,"start":1602,"enrollment":96,"conditions":1603,"interventions":1606},"NCT04140968","Progesterone and Resting Energy Expenditure",[91],"2021-05-27","2019-11-01",[400,1604,1605],"Progesterone","Weight Gain",[1585],{"trials":1608,"activeCount":100},[],{"intervention":1610,"totalTrials":126,"cells":1611},"Pantoprazole",{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1634},{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[],{"trials":1619,"activeCount":100},[],{"trials":1621,"activeCount":100},[1622],{"nctId":1623,"briefTitle":1624,"status":156,"phases":1625,"primaryCompletion":1626,"completion":1626,"start":945,"enrollment":1627,"conditions":1628,"interventions":1633},"NCT02718261","Sup-Icu RENal (SIREN)",[91],"2018-09",3350,[1105,1629,1630,1631,1632],"Acute Kidney Injury","End-stage Renal Disease","Renal Replacement Therapy","Proton Pump Inhibitor",[1610],{"trials":1635,"activeCount":100},[],{"intervention":1637,"totalTrials":126,"cells":1638},"Amoxicillin\u002Fclavulanic acid",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1661},{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"trials":1646,"activeCount":100},[],{"trials":1648,"activeCount":100},[1649],{"nctId":1650,"briefTitle":1651,"status":1041,"phases":1652,"primaryCompletion":1653,"completion":1654,"start":1655,"enrollment":1656,"conditions":1657,"interventions":1659},"NCT01583062","Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures",[91],"2012-11","2012-12","2006-01",217,[1658],"Surgical Wound Infection",[1637,1660],"Amoxicillin plus placebo",{"trials":1662,"activeCount":100},[],{"intervention":1660,"totalTrials":126,"cells":1664},{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1671,"PHASE4":1673,"NA":1679},{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[],{"trials":1674,"activeCount":100},[1675],{"nctId":1650,"briefTitle":1651,"status":1041,"phases":1676,"primaryCompletion":1653,"completion":1654,"start":1655,"enrollment":1656,"conditions":1677,"interventions":1678},[91],[1658],[1637,1660],{"trials":1680,"activeCount":100},[],{"intervention":1682,"totalTrials":126,"cells":1683},"Cangrelor",{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1688,"PHASE3":1690,"PHASE4":1692,"NA":1707},{"trials":1685,"activeCount":100},[],{"trials":1687,"activeCount":100},[],{"trials":1689,"activeCount":100},[],{"trials":1691,"activeCount":100},[],{"trials":1693,"activeCount":100},[1694],{"nctId":1695,"briefTitle":1696,"status":156,"phases":1697,"primaryCompletion":1698,"completion":1699,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1704},"NCT02978040","Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.",[91],"2019-08-26","2019-12-27","2017-07-04",122,[15,1703],"STEMI - ST Elevation Myocardial Infarction",[1682,1705,1706],"Tirofiban","Prasugrel",{"trials":1708,"activeCount":100},[],{"intervention":1705,"totalTrials":126,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1717,"PHASE4":1719,"NA":1725},{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[],{"trials":1716,"activeCount":100},[],{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[1721],{"nctId":1695,"briefTitle":1696,"status":156,"phases":1722,"primaryCompletion":1698,"completion":1699,"start":1700,"enrollment":1701,"conditions":1723,"interventions":1724},[91],[15,1703],[1682,1705,1706],{"trials":1726,"activeCount":100},[],{"intervention":1706,"totalTrials":126,"cells":1728},{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1735,"PHASE4":1737,"NA":1743},{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[],{"trials":1734,"activeCount":100},[],{"trials":1736,"activeCount":100},[],{"trials":1738,"activeCount":100},[1739],{"nctId":1695,"briefTitle":1696,"status":156,"phases":1740,"primaryCompletion":1698,"completion":1699,"start":1700,"enrollment":1701,"conditions":1741,"interventions":1742},[91],[15,1703],[1682,1705,1706],{"trials":1744,"activeCount":100},[],{"intervention":1746,"totalTrials":126,"cells":1747},"Rasagiline",{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1768},{"trials":1749,"activeCount":100},[],{"trials":1751,"activeCount":100},[],{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[1758],{"nctId":1759,"briefTitle":1760,"status":1041,"phases":1761,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1767},"NCT02068625","Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment",[91],"2018-12-31","2010-09",23,[1766],"Retinal Detachment",[1746],{"trials":1769,"activeCount":100},[],{"intervention":1771,"totalTrials":126,"cells":1772},"Paracetamol",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1792},{"trials":1774,"activeCount":100},[],{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[1783],{"nctId":1784,"briefTitle":1785,"status":1041,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1791},"NCT05088876","Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control",[91],"2026-03-05","2024-08-28",7,[24],[1771],{"trials":1793,"activeCount":100},[],{"intervention":1795,"totalTrials":126,"cells":1796},"Propofol and Remifentanil",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1803,"PHASE4":1805,"NA":1820},{"trials":1798,"activeCount":100},[],{"trials":1800,"activeCount":100},[],{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[1807],{"nctId":1808,"briefTitle":1809,"status":156,"phases":1810,"primaryCompletion":1811,"completion":1811,"start":1424,"enrollment":1812,"conditions":1813,"interventions":1816},"NCT02457442","Interaction of Sevoflurane Propofol and Remifentanil in Anesthesia for Laparoscopic Surgery",[91],"2023-10-23",172,[1814,1815],"Drug Interactions","Anesthesia, Conduction",[1795,1795,1817,1817,1818,1819],"Sevoflurane and Remifentanil","SPR 1","SPR2",{"trials":1821,"activeCount":100},[],{"intervention":1817,"totalTrials":126,"cells":1823},{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1838},{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[],{"trials":1831,"activeCount":100},[],{"trials":1833,"activeCount":100},[1834],{"nctId":1808,"briefTitle":1809,"status":156,"phases":1835,"primaryCompletion":1811,"completion":1811,"start":1424,"enrollment":1812,"conditions":1836,"interventions":1837},[91],[1814,1815],[1795,1795,1817,1817,1818,1819],{"trials":1839,"activeCount":100},[],{"intervention":1818,"totalTrials":126,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1856},{"trials":1843,"activeCount":100},[],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":100},[],{"trials":1849,"activeCount":100},[],{"trials":1851,"activeCount":100},[1852],{"nctId":1808,"briefTitle":1809,"status":156,"phases":1853,"primaryCompletion":1811,"completion":1811,"start":1424,"enrollment":1812,"conditions":1854,"interventions":1855},[91],[1814,1815],[1795,1795,1817,1817,1818,1819],{"trials":1857,"activeCount":100},[],{"intervention":1819,"totalTrials":126,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1866,"PHASE4":1868,"NA":1874},{"trials":1861,"activeCount":100},[],{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":100},[],{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[1870],{"nctId":1808,"briefTitle":1809,"status":156,"phases":1871,"primaryCompletion":1811,"completion":1811,"start":1424,"enrollment":1812,"conditions":1872,"interventions":1873},[91],[1814,1815],[1795,1795,1817,1817,1818,1819],{"trials":1875,"activeCount":100},[],{"intervention":1877,"totalTrials":126,"cells":1878},"Diclofenac",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1885,"PHASE4":1887,"NA":1901},{"trials":1880,"activeCount":100},[],{"trials":1882,"activeCount":100},[],{"trials":1884,"activeCount":100},[],{"trials":1886,"activeCount":100},[],{"trials":1888,"activeCount":100},[1889],{"nctId":1890,"briefTitle":1891,"status":1041,"phases":1892,"primaryCompletion":1893,"completion":1894,"start":1895,"enrollment":1896,"conditions":1897,"interventions":1899},"NCT01039545","Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.",[91],"2014-12","2015-01","2012-02",253,[1898],"Urinary Tract Infections",[1877,1900],"Norfloxacin",{"trials":1902,"activeCount":100},[],{"intervention":1900,"totalTrials":126,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1919},{"trials":1906,"activeCount":100},[],{"trials":1908,"activeCount":100},[],{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[1915],{"nctId":1890,"briefTitle":1891,"status":1041,"phases":1916,"primaryCompletion":1893,"completion":1894,"start":1895,"enrollment":1896,"conditions":1917,"interventions":1918},[91],[1898],[1877,1900],{"trials":1920,"activeCount":100},[],{"intervention":1922,"totalTrials":126,"cells":1923},"Ropivacaine 2mg\u002Fml",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1944},{"trials":1925,"activeCount":100},[],{"trials":1927,"activeCount":100},[],{"trials":1929,"activeCount":100},[],{"trials":1931,"activeCount":100},[],{"trials":1933,"activeCount":100},[1934],{"nctId":1935,"briefTitle":1936,"status":156,"phases":1937,"primaryCompletion":1938,"completion":1938,"start":1423,"enrollment":1939,"conditions":1940,"interventions":1942},"NCT02414373","Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Bladder Function",[91],"2017-05-15",42,[1941],"Post Operative Urinary Retention",[1922,1943],"Bupivacaine",{"trials":1945,"activeCount":100},[],{"intervention":1943,"totalTrials":126,"cells":1947},{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1952,"PHASE3":1954,"PHASE4":1956,"NA":1962},{"trials":1949,"activeCount":100},[],{"trials":1951,"activeCount":100},[],{"trials":1953,"activeCount":100},[],{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[1958],{"nctId":1935,"briefTitle":1936,"status":156,"phases":1959,"primaryCompletion":1938,"completion":1938,"start":1423,"enrollment":1939,"conditions":1960,"interventions":1961},[91],[1941],[1922,1943],{"trials":1963,"activeCount":100},[],{"intervention":1965,"totalTrials":126,"cells":1966},"oxycodone\u002Fnaloxone",{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1993},{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":100},[],{"trials":1972,"activeCount":100},[],{"trials":1974,"activeCount":100},[],{"trials":1976,"activeCount":100},[1977],{"nctId":1978,"briefTitle":1979,"status":156,"phases":1980,"primaryCompletion":1981,"completion":1982,"start":1983,"enrollment":1984,"conditions":1985,"interventions":1991},"NCT02516059","Early Postoperative Administration of Oxycodone +\u002F- Naloxone and Duration of Epidural Analgesia",[91],"2017-02-20","2017-02-28","2015-09-14",90,[1986,1987,1988,1989,1990],"Postoperative Pain Management","Radical Cystectomy","Epidural Analgesia","Oral Oxycodone With\u002FWithout Naloxone","Return of the Bowel Function",[1965,1992],"Oxycodone",{"trials":1994,"activeCount":100},[],{"intervention":1992,"totalTrials":126,"cells":1996},{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2005,"NA":2011},{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[2007],{"nctId":1978,"briefTitle":1979,"status":156,"phases":2008,"primaryCompletion":1981,"completion":1982,"start":1983,"enrollment":1984,"conditions":2009,"interventions":2010},[91],[1986,1987,1988,1989,1990],[1965,1992],{"trials":2012,"activeCount":100},[],{"intervention":2014,"totalTrials":126,"cells":2015},"Virosomal influenza vaccine",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2024,"NA":2038},{"trials":2017,"activeCount":100},[],{"trials":2019,"activeCount":100},[],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[],{"trials":2025,"activeCount":100},[2026],{"nctId":2027,"briefTitle":2028,"status":156,"phases":2029,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":2034,"interventions":2036},"NCT00783380","Influenza Vaccination in Immunocompromized Patients",[91],"2006-07","2008-03","2005-10",304,[2035],"Immunosuppression",[2014,2037],"Subunit influenza vaccine",{"trials":2039,"activeCount":100},[],{"intervention":2037,"totalTrials":126,"cells":2041},{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2048,"PHASE4":2050,"NA":2056},{"trials":2043,"activeCount":100},[],{"trials":2045,"activeCount":100},[],{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[],{"trials":2051,"activeCount":100},[2052],{"nctId":2027,"briefTitle":2028,"status":156,"phases":2053,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":2054,"interventions":2055},[91],[2035],[2014,2037],{"trials":2057,"activeCount":100},[],{"intervention":2059,"totalTrials":126,"cells":2060},"Metamizole Sodium",{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2067,"PHASE4":2069,"NA":2081},{"trials":2062,"activeCount":100},[],{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[2071],{"nctId":2072,"briefTitle":2073,"status":2074,"phases":2075,"primaryCompletion":2076,"completion":59,"start":2077,"enrollment":630,"conditions":2078,"interventions":2079},"NCT04111315","Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute Low Back Pain","UNKNOWN",[91],"2025-12-30","2019-12-15",[1428],[2059,2080],"Ibuprofen 600 mg",{"trials":2082,"activeCount":100},[],{"intervention":2080,"totalTrials":126,"cells":2084},{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2093,"NA":2099},{"trials":2086,"activeCount":100},[],{"trials":2088,"activeCount":100},[],{"trials":2090,"activeCount":100},[],{"trials":2092,"activeCount":100},[],{"trials":2094,"activeCount":100},[2095],{"nctId":2072,"briefTitle":2073,"status":2074,"phases":2096,"primaryCompletion":2076,"completion":59,"start":2077,"enrollment":630,"conditions":2097,"interventions":2098},[91],[1428],[2059,2080],{"trials":2100,"activeCount":100},[],{"intervention":176,"totalTrials":126,"cells":2102},{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2109,"PHASE4":2111,"NA":2117},{"trials":2104,"activeCount":100},[],{"trials":2106,"activeCount":100},[],{"trials":2108,"activeCount":100},[],{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[2113],{"nctId":167,"briefTitle":168,"status":156,"phases":2114,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":2115,"interventions":2116},[91],[15,174],[176,140,177,178],{"trials":2118,"activeCount":100},[],{"intervention":178,"totalTrials":126,"cells":2120},{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2127,"PHASE4":2129,"NA":2135},{"trials":2122,"activeCount":100},[],{"trials":2124,"activeCount":100},[],{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":100},[],{"trials":2130,"activeCount":100},[2131],{"nctId":167,"briefTitle":168,"status":156,"phases":2132,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":2133,"interventions":2134},[91],[15,174],[176,140,177,178],{"trials":2136,"activeCount":100},[],{"intervention":2138,"totalTrials":126,"cells":2139},"NUTROF TOTAL",{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2146,"PHASE4":2148,"NA":2159},{"trials":2141,"activeCount":100},[],{"trials":2143,"activeCount":100},[],{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":100},[],{"trials":2149,"activeCount":100},[2150],{"nctId":2151,"briefTitle":2152,"status":156,"phases":2153,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":996,"conditions":2156,"interventions":2158},"NCT04761341","FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment",[91],"2019-10-22","2018-06-01",[2157],"Age Related Macular Degeneration",[2138],{"trials":2160,"activeCount":100},[],{"intervention":2162,"totalTrials":126,"cells":2163},"doxycycline",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2183},{"trials":2165,"activeCount":100},[],{"trials":2167,"activeCount":100},[],{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[2174],{"nctId":2175,"briefTitle":2176,"status":1041,"phases":2177,"primaryCompletion":2178,"completion":2178,"start":1653,"enrollment":1333,"conditions":2179,"interventions":2182},"NCT01879930","Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study",[91],"2015-03",[2180,2181],"Chronic Pelvic Pain Syndrome","Bladder Pain Syndrome",[2162],{"trials":2184,"activeCount":100},[],{"intervention":2186,"totalTrials":126,"cells":2187},"Levothyroxin",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2207},{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[2198],{"nctId":2199,"briefTitle":2200,"status":156,"phases":2201,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":460,"conditions":2204,"interventions":2206},"NCT04354896","The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism",[91],"2018-05-04","2014-05",[1375,2205],"Sarcopenia",[2186],{"trials":2208,"activeCount":100},[],{"intervention":2210,"totalTrials":126,"cells":2211},"Iron carboxymaltose",{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2220,"NA":2231},{"trials":2213,"activeCount":100},[],{"trials":2215,"activeCount":100},[],{"trials":2217,"activeCount":100},[],{"trials":2219,"activeCount":100},[],{"trials":2221,"activeCount":100},[2222],{"nctId":2223,"briefTitle":2224,"status":156,"phases":2225,"primaryCompletion":2226,"completion":2226,"start":2227,"enrollment":2228,"conditions":2229,"interventions":2230},"NCT01519830","Iron Substitution in Blood Donors",[91],"2013-01","2012-01",405,[1385],[2210],{"trials":2232,"activeCount":100},[],{"intervention":2234,"totalTrials":126,"cells":2235},"Metronidazole",{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2244,"NA":2256},{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[],{"trials":2241,"activeCount":100},[],{"trials":2243,"activeCount":100},[],{"trials":2245,"activeCount":100},[2246],{"nctId":2247,"briefTitle":2248,"status":156,"phases":2249,"primaryCompletion":2250,"completion":2250,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2255},"NCT02042287","Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis",[91],"2020-03-19","2014-06",32,[2254],"Bacterial Vaginosis",[2234],{"trials":2257,"activeCount":100},[],{"intervention":2259,"totalTrials":126,"cells":2260},"Hyperoncotic Albumin 20%",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2267,"PHASE4":2269,"NA":2281},{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":100},[2271],{"nctId":2272,"briefTitle":2273,"status":156,"phases":2274,"primaryCompletion":1468,"completion":2275,"start":2276,"enrollment":1939,"conditions":2277,"interventions":2278},"NCT05391607","Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement",[91],"2023-04-10","2022-05-25",[1533,1534],[2259,2279,2280],"Isooncotic Albumin 5%","Ringer's Lactate Crystalloid Solutions",{"trials":2282,"activeCount":100},[],{"intervention":2279,"totalTrials":126,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2293,"NA":2299},{"trials":2286,"activeCount":100},[],{"trials":2288,"activeCount":100},[],{"trials":2290,"activeCount":100},[],{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":100},[2295],{"nctId":2272,"briefTitle":2273,"status":156,"phases":2296,"primaryCompletion":1468,"completion":2275,"start":2276,"enrollment":1939,"conditions":2297,"interventions":2298},[91],[1533,1534],[2259,2279,2280],{"trials":2300,"activeCount":100},[],{"intervention":2280,"totalTrials":126,"cells":2302},{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2309,"PHASE4":2311,"NA":2317},{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":100},[2313],{"nctId":2272,"briefTitle":2273,"status":156,"phases":2314,"primaryCompletion":1468,"completion":2275,"start":2276,"enrollment":1939,"conditions":2315,"interventions":2316},[91],[1533,1534],[2259,2279,2280],{"trials":2318,"activeCount":100},[],{"intervention":2320,"totalTrials":126,"cells":2321},"Clonidine",{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2330,"NA":2344},{"trials":2323,"activeCount":100},[],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":100},[],{"trials":2329,"activeCount":100},[],{"trials":2331,"activeCount":100},[2332],{"nctId":2333,"briefTitle":2334,"status":156,"phases":2335,"primaryCompletion":2336,"completion":2336,"start":2337,"enrollment":172,"conditions":2338,"interventions":2343},"NCT04828226","Clonidine to Prevent Delirium After Electroconvulsive Therapy.",[91],"2026-05-16","2021-04-27",[2339,2340,2341,2342],"Major Depressive Disorder","Catatonia","Bipolar Disorder","Delirium Postseizure",[2320],{"trials":2345,"activeCount":100},[],{"intervention":2347,"totalTrials":126,"cells":2348},"Aprepitant 80 mg",{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2353,"PHASE3":2355,"PHASE4":2357,"NA":2370},{"trials":2350,"activeCount":100},[],{"trials":2352,"activeCount":100},[],{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[2359],{"nctId":2360,"briefTitle":2361,"status":1041,"phases":2362,"primaryCompletion":2363,"completion":2363,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2369},"NCT05189756","Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.",[91],"2025-02-20","2022-03-17",71,[2367,2368],"Postoperative Nausea and Vomiting","Bariatric Surgery",[2347],{"trials":2371,"activeCount":100},[],{"intervention":2373,"totalTrials":96,"cells":2374},"Forxiga 10mg",{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2379,"PHASE3":2381,"PHASE4":2402,"NA":2404},{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[2383,2392],{"nctId":2384,"briefTitle":2385,"status":156,"phases":2386,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":927,"conditions":2389,"interventions":2391},"NCT04035031","Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes",[90],"2020-11-12","2020-01-09",[2390],"Diabetes Mellitus, Type 1",[2373],{"nctId":2393,"briefTitle":2394,"status":156,"phases":2395,"primaryCompletion":2396,"completion":2397,"start":2398,"enrollment":2399,"conditions":2400,"interventions":2401},"NCT04049110","Dapagliflozin in Physical Exercise in Type 1 Diabetes",[90],"2023-04-26","2023-05-10","2020-08-25",39,[2390],[2373],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"intervention":1416,"totalTrials":96,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2424,"NA":2426},{"trials":2409,"activeCount":100},[],{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[2416,2420],{"nctId":1408,"briefTitle":1409,"status":156,"phases":2417,"primaryCompletion":1411,"completion":1412,"start":170,"enrollment":1413,"conditions":2418,"interventions":2419},[90],[24],[1416,1417,1418],{"nctId":1420,"briefTitle":1421,"status":156,"phases":2421,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":2422,"interventions":2423},[90],[1428],[1430,1431,1432,1397],{"trials":2425,"activeCount":100},[],{"trials":2427,"activeCount":100},[],{"intervention":2429,"totalTrials":96,"cells":2430},"Colchicine",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2463,"NA":2465},{"trials":2432,"activeCount":100},[],{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[],{"trials":2438,"activeCount":100},[2439,2451],{"nctId":2440,"briefTitle":2441,"status":1041,"phases":2442,"primaryCompletion":2443,"completion":2443,"start":2444,"enrollment":2445,"conditions":2446,"interventions":2449},"NCT04516941","CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19",[90],"2022-08-31","2021-01-21",60,[2447,2448],"SARS-CoV Infection","COVID-19",[2450,2429],"Edoxaban",{"nctId":2452,"briefTitle":2453,"status":156,"phases":2454,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":630,"conditions":2458,"interventions":2462},"NCT04870424","Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement",[90],"2024-05-26","2025-06-03","2021-09-21",[2459,2460,2461,2429],"Transcatheter Aortic Valve Replacement","Atrial Fibrillation New Onset","Pacemaker",[2429],{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[],{"intervention":2468,"totalTrials":126,"cells":2469},"12.5 mg hydrochlorothiazide",{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2476,"PHASE4":2490,"NA":2492},{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[2478],{"nctId":2479,"briefTitle":2480,"status":156,"phases":2481,"primaryCompletion":2482,"completion":2483,"start":2484,"enrollment":2485,"conditions":2486,"interventions":2487},"NCT03057431","Hydrochlorothiazide for Kidney Stone Recurrence Prevention",[90],"2021-12-03","2022-04-30","2017-03-09",416,[542],[2468,2488,2489],"25.0 mg hydrochlorothiazide","50.0 mg hydrochlorothiazide",{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"intervention":2488,"totalTrials":126,"cells":2495},{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2502,"PHASE4":2508,"NA":2510},{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[],{"trials":2503,"activeCount":100},[2504],{"nctId":2479,"briefTitle":2480,"status":156,"phases":2505,"primaryCompletion":2482,"completion":2483,"start":2484,"enrollment":2485,"conditions":2506,"interventions":2507},[90],[542],[2468,2488,2489],{"trials":2509,"activeCount":100},[],{"trials":2511,"activeCount":100},[],{"intervention":2489,"totalTrials":126,"cells":2513},{"EARLY_PHASE1":2514,"PHASE1":2516,"PHASE2":2518,"PHASE3":2520,"PHASE4":2526,"NA":2528},{"trials":2515,"activeCount":100},[],{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":100},[],{"trials":2521,"activeCount":100},[2522],{"nctId":2479,"briefTitle":2480,"status":156,"phases":2523,"primaryCompletion":2482,"completion":2483,"start":2484,"enrollment":2485,"conditions":2524,"interventions":2525},[90],[542],[2468,2488,2489],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"intervention":2531,"totalTrials":126,"cells":2532},"Tenecteplase",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2550,"NA":2552},{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"trials":2540,"activeCount":100},[2541],{"nctId":2542,"briefTitle":2543,"status":156,"phases":2544,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":2547,"conditions":2548,"interventions":2549},"NCT05499832","Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions",[90],"2025-10-09","2023-03-21",156,[29],[2531],{"trials":2551,"activeCount":100},[],{"trials":2553,"activeCount":100},[],{"intervention":2555,"totalTrials":126,"cells":2556},"Alirocumab",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2577,"NA":2579},{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":100},[],{"trials":2562,"activeCount":100},[],{"trials":2564,"activeCount":100},[2565],{"nctId":2566,"briefTitle":2567,"status":156,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":2571,"conditions":2572,"interventions":2576},"NCT03067844","Vascular Effects of Alirocumab in Acute MI-Patients",[90],"2021-10-13","2017-04-25",294,[2573,2574,2575],"Coronary Vessel","Coronary Circulation","Atheroma; Myocardial",[2555],{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"intervention":1417,"totalTrials":126,"cells":2582},{"EARLY_PHASE1":2583,"PHASE1":2585,"PHASE2":2587,"PHASE3":2589,"PHASE4":2595,"NA":2597},{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[],{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[2591],{"nctId":1408,"briefTitle":1409,"status":156,"phases":2592,"primaryCompletion":1411,"completion":1412,"start":170,"enrollment":1413,"conditions":2593,"interventions":2594},[90],[24],[1416,1417,1418],{"trials":2596,"activeCount":100},[],{"trials":2598,"activeCount":100},[],{"intervention":2600,"totalTrials":126,"cells":2601},"Omalizumab",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2608,"PHASE4":2621,"NA":2623},{"trials":2603,"activeCount":100},[],{"trials":2605,"activeCount":100},[],{"trials":2607,"activeCount":100},[],{"trials":2609,"activeCount":100},[2610],{"nctId":2611,"briefTitle":2612,"status":156,"phases":2613,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":16,"conditions":2616,"interventions":2620},"NCT01803763","Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients",[89,90],"2014-03","2012-09",[2617,2618,2619],"Chronic Urticaria","Chronic Idiopathic Urticaria","Chronic Spontaneous Urticaria",[2600],{"trials":2622,"activeCount":100},[],{"trials":2624,"activeCount":100},[],{"intervention":2626,"totalTrials":126,"cells":2627},"Evolocumab 140 mg\u002FmL",{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2647,"NA":2649},{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":100},[],{"trials":2635,"activeCount":100},[2636],{"nctId":2637,"briefTitle":2638,"status":156,"phases":2639,"primaryCompletion":2640,"completion":2641,"start":2642,"enrollment":2643,"conditions":2644,"interventions":2646},"NCT03287609","EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)",[90],"2019-05-20","2019-08-07","2018-01-23",308,[2645],"Acute Coronary Syndrome",[2626],{"trials":2648,"activeCount":100},[],{"trials":2650,"activeCount":100},[],{"intervention":2652,"totalTrials":126,"cells":2653},"Cortisol 20mg",{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2658,"PHASE3":2660,"PHASE4":2671,"NA":2673},{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[],{"trials":2659,"activeCount":100},[],{"trials":2661,"activeCount":100},[2662],{"nctId":2663,"briefTitle":2664,"status":156,"phases":2665,"primaryCompletion":926,"completion":926,"start":1441,"enrollment":1442,"conditions":2666,"interventions":2670},"NCT02196142","Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence",[90],[2667,2668,2669],"Alcohol Craving","Psychological Stress","Physiological Stress",[2652],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[],{"intervention":2676,"totalTrials":126,"cells":2677},"lidocaine",{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2684,"PHASE4":2695,"NA":2697},{"trials":2679,"activeCount":100},[],{"trials":2681,"activeCount":100},[],{"trials":2683,"activeCount":100},[],{"trials":2685,"activeCount":100},[2686],{"nctId":2687,"briefTitle":2688,"status":156,"phases":2689,"primaryCompletion":2690,"completion":2690,"start":2691,"enrollment":2692,"conditions":2693,"interventions":2694},"NCT00789620","Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery",[90],"2011-03","2008-11",76,[24,1385],[2676],{"trials":2696,"activeCount":100},[],{"trials":2698,"activeCount":100},[],{"intervention":2700,"totalTrials":126,"cells":2701},"Tadalafil 20 MG",{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2708,"PHASE4":2720,"NA":2722},{"trials":2703,"activeCount":100},[],{"trials":2705,"activeCount":100},[],{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[2710],{"nctId":2711,"briefTitle":2712,"status":156,"phases":2713,"primaryCompletion":2714,"completion":2714,"start":2715,"enrollment":858,"conditions":2716,"interventions":2719},"NCT03049540","Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function",[90],"2021-10-28","2017-10-25",[2717,2718],"Heart Defects, Congenital","Transposition of Great Vessels With Ventricular Inversion",[2700],{"trials":2721,"activeCount":100},[],{"trials":2723,"activeCount":100},[],{"intervention":2450,"totalTrials":126,"cells":2725},{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2732,"PHASE4":2738,"NA":2740},{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":100},[],{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[2734],{"nctId":2440,"briefTitle":2441,"status":1041,"phases":2735,"primaryCompletion":2443,"completion":2443,"start":2444,"enrollment":2445,"conditions":2736,"interventions":2737},[90],[2447,2448],[2450,2429],{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[],{"intervention":2743,"totalTrials":126,"cells":2744},"Heparin",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2749,"PHASE3":2751,"PHASE4":2764,"NA":2766},{"trials":2746,"activeCount":100},[],{"trials":2748,"activeCount":100},[],{"trials":2750,"activeCount":100},[],{"trials":2752,"activeCount":100},[2753],{"nctId":2754,"briefTitle":2755,"status":2756,"phases":2757,"primaryCompletion":2758,"completion":2759,"start":2760,"enrollment":100,"conditions":2761,"interventions":2763},"NCT03422419","TIPS or Anticoagulation in Portal Vein Thrombosis","WITHDRAWN",[90],"2020-10-31","2021-07-31","2018-08-01",[2762],"Thrombosis Portal Vein",[2743],{"trials":2765,"activeCount":100},[],{"trials":2767,"activeCount":100},[],{"intervention":1430,"totalTrials":126,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2776,"PHASE4":2782,"NA":2784},{"trials":2771,"activeCount":100},[],{"trials":2773,"activeCount":100},[],{"trials":2775,"activeCount":100},[],{"trials":2777,"activeCount":100},[2778],{"nctId":1420,"briefTitle":1421,"status":156,"phases":2779,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":2780,"interventions":2781},[90],[1428],[1430,1431,1432,1397],{"trials":2783,"activeCount":100},[],{"trials":2785,"activeCount":100},[],{"intervention":1432,"totalTrials":126,"cells":2787},{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2792,"PHASE3":2794,"PHASE4":2800,"NA":2802},{"trials":2789,"activeCount":100},[],{"trials":2791,"activeCount":100},[],{"trials":2793,"activeCount":100},[],{"trials":2795,"activeCount":100},[2796],{"nctId":1420,"briefTitle":1421,"status":156,"phases":2797,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":2798,"interventions":2799},[90],[1428],[1430,1431,1432,1397],{"trials":2801,"activeCount":100},[],{"trials":2803,"activeCount":100},[],{"intervention":2805,"totalTrials":126,"cells":2806},"Botulinum toxin type A",{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2811,"PHASE3":2813,"PHASE4":2824,"NA":2826},{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":100},[],{"trials":2814,"activeCount":100},[2815],{"nctId":2816,"briefTitle":2817,"status":156,"phases":2818,"primaryCompletion":39,"completion":39,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2823},"NCT03459092","Botox Instead of Strabismus Surgery (BISS)",[90],"2018-08-16",63,[2822],"Acquired Esotropia",[2805],{"trials":2825,"activeCount":100},[],{"trials":2827,"activeCount":100},[],{"intervention":2829,"totalTrials":126,"cells":2830},"Insulin Degludec",{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2837,"PHASE4":2849,"NA":2851},{"trials":2832,"activeCount":100},[],{"trials":2834,"activeCount":100},[],{"trials":2836,"activeCount":100},[],{"trials":2838,"activeCount":100},[2839],{"nctId":2840,"briefTitle":2841,"status":156,"phases":2842,"primaryCompletion":2843,"completion":2843,"start":2844,"enrollment":2845,"conditions":2846,"interventions":2848},"NCT03387787","Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2",[89,90],"2020-01-30","2018-01-30",15,[2847],"Type 2 Diabetes Mellitus",[2829],{"trials":2850,"activeCount":100},[],{"trials":2852,"activeCount":100},[],{"intervention":2854,"totalTrials":126,"cells":2855},"Chemotherapy",{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2860,"PHASE3":2862,"PHASE4":2874,"NA":2876},{"trials":2857,"activeCount":100},[],{"trials":2859,"activeCount":100},[],{"trials":2861,"activeCount":100},[],{"trials":2863,"activeCount":100},[2864],{"nctId":2865,"briefTitle":2866,"status":156,"phases":2867,"primaryCompletion":2868,"completion":2868,"start":2869,"enrollment":2870,"conditions":2871,"interventions":2873},"NCT02918955","Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection",[90],"2025-06-24","2016-12-16",65,[2872],"Head and Neck Neoplasms",[2854],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[],{"intervention":2879,"totalTrials":141,"cells":2880},"Gemcitabine",{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2896,"PHASE3":2918,"PHASE4":2920,"NA":2922},{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[2885],{"nctId":2886,"briefTitle":2887,"status":2756,"phases":2888,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":100,"conditions":2891,"interventions":2893},"NCT05738161","Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma",[88],"2024-02-27","2023-06-21",[2892],"Advanced Urothelial Carcinoma",[2894,2895,2879],"Magrolimab","Cisplatin",{"trials":2897,"activeCount":100},[2898,2908],{"nctId":2899,"briefTitle":2900,"status":156,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2614,"enrollment":2903,"conditions":2904,"interventions":2906},"NCT02791373","Vinorelbine and Gemcitabine in Myeloma",[89],"2017-12-31",136,[632,2905],"Amyloidosis",[2907,2879],"Vinorelbine",{"nctId":2909,"briefTitle":2910,"status":156,"phases":2911,"primaryCompletion":2912,"completion":135,"start":2913,"enrollment":2914,"conditions":2915,"interventions":2916},"NCT03442673","Chemotherapy and G-CSF for Mobilization",[89],"2023-03-01","2018-09-17",137,[632],[2907,2879,2917],"G-CSF",{"trials":2919,"activeCount":100},[],{"trials":2921,"activeCount":100},[],{"trials":2923,"activeCount":100},[],{"intervention":2925,"totalTrials":96,"cells":2926},"Tocilizumab",{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2931,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2928,"activeCount":100},[],{"trials":2930,"activeCount":100},[],{"trials":2932,"activeCount":100},[2933,2942],{"nctId":2934,"briefTitle":2935,"status":1041,"phases":2936,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":1333,"conditions":2939,"interventions":2941},"NCT04335071","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)",[89],"2020-09-27","2020-04-26",[2940],"SARS-CoV-2 Infection",[2925],{"nctId":2943,"briefTitle":2944,"status":156,"phases":2945,"primaryCompletion":2946,"completion":2947,"start":2948,"enrollment":2949,"conditions":2950,"interventions":2951},"NCT03745586","Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab",[88,89],"2020-11-30","2021-03-01","2018-12-01",18,[772],[2925,2952],"Glucocorticoids",{"trials":2954,"activeCount":100},[],{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":100},[],{"intervention":2907,"totalTrials":96,"cells":2960},{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2975,"PHASE4":2977,"NA":2979},{"trials":2962,"activeCount":100},[],{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[2967,2971],{"nctId":2899,"briefTitle":2900,"status":156,"phases":2968,"primaryCompletion":2902,"completion":2902,"start":2614,"enrollment":2903,"conditions":2969,"interventions":2970},[89],[632,2905],[2907,2879],{"nctId":2909,"briefTitle":2910,"status":156,"phases":2972,"primaryCompletion":2912,"completion":135,"start":2913,"enrollment":2914,"conditions":2973,"interventions":2974},[89],[632],[2907,2879,2917],{"trials":2976,"activeCount":100},[],{"trials":2978,"activeCount":100},[],{"trials":2980,"activeCount":100},[],{"intervention":2982,"totalTrials":96,"cells":2983},"Rivaroxaban",{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":2999,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":2985,"activeCount":100},[],{"trials":2987,"activeCount":100},[2988],{"nctId":2989,"briefTitle":2990,"status":156,"phases":2991,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":2994,"conditions":2995,"interventions":2997},"NCT03796377","Rivaroxaban Hypericum Trial",[88],"2019-04-09","2019-02-13",12,[2996],"Drug Interaction Study",[2998,2982],"St Johns Wort Extract",{"trials":3000,"activeCount":100},[3001],{"nctId":3002,"briefTitle":3003,"status":1041,"phases":3004,"primaryCompletion":3005,"completion":3005,"start":2615,"enrollment":2994,"conditions":3006,"interventions":3010},"NCT02128841","Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.",[89],"2017-09",[3007,3008,3009],"Aortic Valve Disease","Heart Valve Prosthesis Implantation","Anticoagulants",[2982],{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"intervention":3018,"totalTrials":96,"cells":3019},"Durvalumab",{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[3026,3038],{"nctId":3027,"briefTitle":3028,"status":1041,"phases":3029,"primaryCompletion":3030,"completion":3031,"start":3032,"enrollment":3033,"conditions":3034,"interventions":3036},"NCT03234153","Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin",[89],"2019-11-08","2020-05-18","2018-07-15",6,[3035],"Muscle-invasive Bladder Cancer",[3018,3037],"Tremelimumab",{"nctId":3039,"briefTitle":3040,"status":2756,"phases":3041,"primaryCompletion":3042,"completion":3043,"start":3044,"enrollment":100,"conditions":3045,"interventions":3047},"NCT03241017","Durvalumab in DLBCL After Autologous Transplant",[89],"2021-10","2021-12","2017-10",[3046],"Lymphoma, Large B-Cell, Diffuse",[3018],{"trials":3049,"activeCount":100},[],{"trials":3051,"activeCount":100},[],{"trials":3053,"activeCount":100},[],{"intervention":3055,"totalTrials":126,"cells":3056},"Tocilizumab + Glucocorticoids",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3071,"PHASE4":3073,"NA":3075},{"trials":3058,"activeCount":100},[],{"trials":3060,"activeCount":100},[],{"trials":3062,"activeCount":100},[3063],{"nctId":3064,"briefTitle":3065,"status":156,"phases":3066,"primaryCompletion":1893,"completion":3067,"start":3068,"enrollment":16,"conditions":3069,"interventions":3070},"NCT01450137","Tocilizumab for Patients With Giant Cell Arteritis",[89],"2015-09","2011-09",[772],[3055],{"trials":3072,"activeCount":100},[],{"trials":3074,"activeCount":100},[],{"trials":3076,"activeCount":100},[],{"intervention":3078,"totalTrials":126,"cells":3079},"Tenofovir Alafenamide",{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3084,"PHASE3":3095,"PHASE4":3097,"NA":3099},{"trials":3081,"activeCount":100},[],{"trials":3083,"activeCount":100},[],{"trials":3085,"activeCount":100},[3086],{"nctId":3087,"briefTitle":3088,"status":156,"phases":3089,"primaryCompletion":3090,"completion":3090,"start":3091,"enrollment":934,"conditions":3092,"interventions":3094},"NCT03115736","TAF for HIV-HBV With Renal Dysfunction",[89],"2019-12-05","2017-05-23",[3093],"HIV and Hepatitis B Coinfection",[3078],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[],{"trials":3100,"activeCount":100},[],{"intervention":3102,"totalTrials":126,"cells":3103},"Interferon beta 1b",{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3122,"PHASE4":3124,"NA":3126},{"trials":3105,"activeCount":100},[],{"trials":3107,"activeCount":100},[],{"trials":3109,"activeCount":100},[3110],{"nctId":3111,"briefTitle":3112,"status":156,"phases":3113,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":3117,"conditions":3118,"interventions":3120},"NCT00942591","Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b",[89],"2009-04","2009-05","2005-05",77,[3119],"Multiple Sclerosis",[3102,3121],"Atorvastatin",{"trials":3123,"activeCount":100},[],{"trials":3125,"activeCount":100},[],{"trials":3127,"activeCount":100},[],{"intervention":3121,"totalTrials":126,"cells":3129},{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3140,"PHASE4":3142,"NA":3144},{"trials":3131,"activeCount":100},[],{"trials":3133,"activeCount":100},[],{"trials":3135,"activeCount":100},[3136],{"nctId":3111,"briefTitle":3112,"status":156,"phases":3137,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":3117,"conditions":3138,"interventions":3139},[89],[3119],[3102,3121],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[],{"intervention":3147,"totalTrials":126,"cells":3148},"Brentuximab Vedotin",{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[],{"trials":3154,"activeCount":100},[3155],{"nctId":3156,"briefTitle":3157,"status":3158,"phases":3159,"primaryCompletion":3160,"completion":3161,"start":3162,"enrollment":1201,"conditions":3163,"interventions":3164},"NCT03187210","Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas","SUSPENDED",[88,89],"2023-11-02","2025-04-30","2018-09-01",[861],[3147,3165],"BeEAM Regimen",{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"trials":3171,"activeCount":100},[],{"intervention":3165,"totalTrials":126,"cells":3173},{"EARLY_PHASE1":3174,"PHASE1":3176,"PHASE2":3178,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3175,"activeCount":100},[],{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":100},[3180],{"nctId":3156,"briefTitle":3157,"status":3158,"phases":3181,"primaryCompletion":3160,"completion":3161,"start":3162,"enrollment":1201,"conditions":3182,"interventions":3183},[88,89],[861],[3147,3165],{"trials":3185,"activeCount":100},[],{"trials":3187,"activeCount":100},[],{"trials":3189,"activeCount":100},[],{"intervention":3191,"totalTrials":126,"cells":3192},"Ibuprofen",{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3197,"PHASE3":3213,"PHASE4":3215,"NA":3217},{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":100},[3199],{"nctId":3200,"briefTitle":3201,"status":156,"phases":3202,"primaryCompletion":3203,"completion":3203,"start":3204,"enrollment":3205,"conditions":3206,"interventions":3212},"NCT02571543","Can Ibuprofen Delay Ovulation in Natural Cycle-IVF?",[89],"2022-08-09","2016-01",51,[3207,3208,3209,3210,3211],"Ovulation","Ovulation Inhibition","Ovulation Inhibition\u002FDrug Effects","Pregnancy","Fertilization in Vitro\u002FMethods",[3191],{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":100},[],{"trials":3218,"activeCount":100},[],{"intervention":3220,"totalTrials":126,"cells":3221},"BeEAM",{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3223,"activeCount":100},[],{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[3228],{"nctId":3229,"briefTitle":3230,"status":156,"phases":3231,"primaryCompletion":3232,"completion":3233,"start":1423,"enrollment":3234,"conditions":3235,"interventions":3238},"NCT02278796","A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)",[89],"2018-11-28","2020-11",108,[3046,3236,3237],"Lymphoma, Follicular","Lymphoma, Mantle-Cell",[3220,3239],"BEAM",{"trials":3241,"activeCount":100},[],{"trials":3243,"activeCount":100},[],{"trials":3245,"activeCount":100},[],{"intervention":3239,"totalTrials":126,"cells":3247},{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3258,"PHASE4":3260,"NA":3262},{"trials":3249,"activeCount":100},[],{"trials":3251,"activeCount":100},[],{"trials":3253,"activeCount":100},[3254],{"nctId":3229,"briefTitle":3230,"status":156,"phases":3255,"primaryCompletion":3232,"completion":3233,"start":1423,"enrollment":3234,"conditions":3256,"interventions":3257},[89],[3046,3236,3237],[3220,3239],{"trials":3259,"activeCount":100},[],{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[],{"intervention":2952,"totalTrials":126,"cells":3265},{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3276,"PHASE4":3278,"NA":3280},{"trials":3267,"activeCount":100},[],{"trials":3269,"activeCount":100},[],{"trials":3271,"activeCount":100},[3272],{"nctId":2943,"briefTitle":2944,"status":156,"phases":3273,"primaryCompletion":2946,"completion":2947,"start":2948,"enrollment":2949,"conditions":3274,"interventions":3275},[88,89],[772],[2925,2952],{"trials":3277,"activeCount":100},[],{"trials":3279,"activeCount":100},[],{"trials":3281,"activeCount":100},[],{"intervention":3283,"totalTrials":126,"cells":3284},"Serotonin Uptake Inhibitors",{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3300,"PHASE4":3302,"NA":3304},{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[3291],{"nctId":3292,"briefTitle":3293,"status":2074,"phases":3294,"primaryCompletion":3295,"completion":3296,"start":3297,"enrollment":1984,"conditions":3298,"interventions":3299},"NCT02865642","Cortical Ischemic Stroke and Serotonin",[89],"2020-09","2020-12","2016-08",[21],[3283],{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[],{"intervention":3037,"totalTrials":126,"cells":3307},{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3312,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3309,"activeCount":100},[],{"trials":3311,"activeCount":100},[],{"trials":3313,"activeCount":100},[3314],{"nctId":3027,"briefTitle":3028,"status":1041,"phases":3315,"primaryCompletion":3030,"completion":3031,"start":3032,"enrollment":3033,"conditions":3316,"interventions":3317},[89],[3035],[3018,3037],{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[],{"intervention":3325,"totalTrials":126,"cells":3326},"Alefacept",{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3331,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3328,"activeCount":100},[],{"trials":3330,"activeCount":100},[],{"trials":3332,"activeCount":100},[3333],{"nctId":3334,"briefTitle":3335,"status":156,"phases":3336,"completion":3337,"start":1655,"enrollment":25,"conditions":3338,"interventions":3340},"NCT00376129","Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis",[89],"2007-01",[3339],"Atopic Dermatitis",[3325],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[],{"intervention":3348,"totalTrials":126,"cells":3349},"oral 18B Glycyrrhetinic acid versus placebo",{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3365,"PHASE4":3367,"NA":3369},{"trials":3351,"activeCount":100},[],{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[3356],{"nctId":3357,"briefTitle":3358,"status":156,"phases":3359,"completion":3360,"start":3361,"enrollment":934,"conditions":3362,"interventions":3364},"NCT00384384","Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients",[89],"2007-04","2006-08",[3363],"End Stage Renal Disease",[3348],{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[],{"intervention":3372,"totalTrials":126,"cells":3373},"Gallium-68-DOTATATE PET\u002FCT",{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3375,"activeCount":100},[],{"trials":3377,"activeCount":100},[],{"trials":3379,"activeCount":100},[3380],{"nctId":3381,"briefTitle":3382,"status":1041,"phases":3383,"primaryCompletion":3297,"completion":3297,"start":2614,"enrollment":397,"conditions":3384,"interventions":3386},"NCT02078843","Diagnostic Accuracy of Gallium-68-DOTATATE PET\u002FCT Compared to Indium-111-pentetreotide Scintigraphy (SPECT\u002FCT) for Gastroenteropancreatic Neuroendocrine Tumors",[88,89],[3385],"Gastroenteropancreatic Neuroendocrine Tumors",[3372,3387],"Indium-111-Octreoscan",{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[],{"intervention":3387,"totalTrials":126,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3406,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":100},[],{"trials":3399,"activeCount":100},[],{"trials":3401,"activeCount":100},[3402],{"nctId":3381,"briefTitle":3382,"status":1041,"phases":3403,"primaryCompletion":3297,"completion":3297,"start":2614,"enrollment":397,"conditions":3404,"interventions":3405},[88,89],[3385],[3372,3387],{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":100},[],{"trials":3411,"activeCount":100},[],{"intervention":3413,"totalTrials":126,"cells":3414},"hCG",{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3431,"PHASE4":3433,"NA":3435},{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[],{"trials":3420,"activeCount":100},[3421],{"nctId":3422,"briefTitle":3423,"status":2756,"phases":3424,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":100,"conditions":3427,"interventions":3429},"NCT04850261","Injection Free IVF",[89],"2024-03-31","2021-05-01",[3428],"Fertility Disorders",[3413,3430],"Nafarelin nasal spray",{"trials":3432,"activeCount":100},[],{"trials":3434,"activeCount":100},[],{"trials":3436,"activeCount":100},[],{"intervention":3430,"totalTrials":126,"cells":3438},{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3449,"PHASE4":3451,"NA":3453},{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[3445],{"nctId":3422,"briefTitle":3423,"status":2756,"phases":3446,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":100,"conditions":3447,"interventions":3448},[89],[3428],[3413,3430],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[],{"trials":3454,"activeCount":100},[],{"intervention":3456,"totalTrials":126,"cells":3457},"Rivaroxaban 10 MG Oral Tablet [Xarelto]",{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3473,"PHASE4":3475,"NA":3477},{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[],{"trials":3463,"activeCount":100},[3464],{"nctId":3465,"briefTitle":3466,"status":156,"phases":3467,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":3470,"conditions":3471,"interventions":3472},"NCT03522259","Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery",[89],"2023-12-31","2018-07-19",272,[2368],[3456],{"trials":3474,"activeCount":100},[],{"trials":3476,"activeCount":100},[],{"trials":3478,"activeCount":100},[],{"intervention":3480,"totalTrials":126,"cells":3481},"Interferon beta-1b group",{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3486,"PHASE3":3497,"PHASE4":3499,"NA":3501},{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[3488],{"nctId":3489,"briefTitle":3490,"status":156,"phases":3491,"primaryCompletion":1411,"completion":1411,"start":3492,"enrollment":996,"conditions":3493,"interventions":3495},"NCT01111656","Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b",[89],"2007-03",[3494],"Relapsing-remitting Multiple Sclerosis",[3480,3496],"Interferon beta-1b\u002FAtorvastatin group",{"trials":3498,"activeCount":100},[],{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"intervention":3496,"totalTrials":126,"cells":3504},{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3509,"PHASE3":3515,"PHASE4":3517,"NA":3519},{"trials":3506,"activeCount":100},[],{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[3511],{"nctId":3489,"briefTitle":3490,"status":156,"phases":3512,"primaryCompletion":1411,"completion":1411,"start":3492,"enrollment":996,"conditions":3513,"interventions":3514},[89],[3494],[3480,3496],{"trials":3516,"activeCount":100},[],{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[],{"intervention":3522,"totalTrials":126,"cells":3523},"Vinorelbine, G-CSF, & Plerixafor",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3528,"PHASE3":3540,"PHASE4":3542,"NA":3544},{"trials":3525,"activeCount":100},[],{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[3530],{"nctId":3531,"briefTitle":3532,"status":156,"phases":3533,"primaryCompletion":2227,"completion":3534,"start":1411,"enrollment":238,"conditions":3535,"interventions":3536},"NCT01220375","PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma",[89],"2013-10",[860],[3522,3537,3538,3539],"Vinorelbine and Plerixafor","G-CSF and Plerixafor","Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells\u002Fml of peripheral blood",{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":100},[],{"trials":3545,"activeCount":100},[],{"intervention":3537,"totalTrials":126,"cells":3547},{"EARLY_PHASE1":3548,"PHASE1":3550,"PHASE2":3552,"PHASE3":3558,"PHASE4":3560,"NA":3562},{"trials":3549,"activeCount":100},[],{"trials":3551,"activeCount":100},[],{"trials":3553,"activeCount":100},[3554],{"nctId":3531,"briefTitle":3532,"status":156,"phases":3555,"primaryCompletion":2227,"completion":3534,"start":1411,"enrollment":238,"conditions":3556,"interventions":3557},[89],[860],[3522,3537,3538,3539],{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"intervention":3538,"totalTrials":126,"cells":3565},{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3570,"PHASE3":3576,"PHASE4":3578,"NA":3580},{"trials":3567,"activeCount":100},[],{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[3572],{"nctId":3531,"briefTitle":3532,"status":156,"phases":3573,"primaryCompletion":2227,"completion":3534,"start":1411,"enrollment":238,"conditions":3574,"interventions":3575},[89],[860],[3522,3537,3538,3539],{"trials":3577,"activeCount":100},[],{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[],{"intervention":3539,"totalTrials":126,"cells":3583},{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3588,"PHASE3":3594,"PHASE4":3596,"NA":3598},{"trials":3585,"activeCount":100},[],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[3590],{"nctId":3531,"briefTitle":3532,"status":156,"phases":3591,"primaryCompletion":2227,"completion":3534,"start":1411,"enrollment":238,"conditions":3592,"interventions":3593},[89],[860],[3522,3537,3538,3539],{"trials":3595,"activeCount":100},[],{"trials":3597,"activeCount":100},[],{"trials":3599,"activeCount":100},[],{"intervention":644,"totalTrials":126,"cells":3601},{"EARLY_PHASE1":3602,"PHASE1":3604,"PHASE2":3606,"PHASE3":3612,"PHASE4":3614,"NA":3616},{"trials":3603,"activeCount":100},[],{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[3608],{"nctId":636,"briefTitle":637,"status":156,"phases":3609,"primaryCompletion":639,"completion":640,"start":641,"enrollment":630,"conditions":3610,"interventions":3611},[89],[632],[615,644],{"trials":3613,"activeCount":100},[],{"trials":3615,"activeCount":100},[],{"trials":3617,"activeCount":100},[],{"intervention":3619,"totalTrials":126,"cells":3620},"folic acid, vitamin B12 and B6 and rosuvastatin",{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"trials":3626,"activeCount":100},[3627],{"nctId":3628,"briefTitle":3629,"status":156,"phases":3630,"primaryCompletion":3631,"completion":3360,"start":3632,"enrollment":811,"conditions":3633,"interventions":3636},"NCT00693589","Effect of Homocysteine-lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease",[89],"2007-02","2005-01",[3634,3635],"Cardiovascular Disease","Endothelial Dysfunction",[3619],{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[],{"intervention":3644,"totalTrials":126,"cells":3645},"Tropisetron 2 mg",{"EARLY_PHASE1":3646,"PHASE1":3648,"PHASE2":3650,"PHASE3":3661,"PHASE4":3663,"NA":3665},{"trials":3647,"activeCount":100},[],{"trials":3649,"activeCount":100},[],{"trials":3651,"activeCount":100},[3652],{"nctId":3653,"briefTitle":3654,"status":156,"phases":3655,"primaryCompletion":1411,"completion":1411,"start":3656,"enrollment":16,"conditions":3657,"interventions":3659},"NCT00889499","Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron",[89],"2009-03",[24,3658],"Chronic Disease",[3644,3660],"Tropisetron 5mg",{"trials":3662,"activeCount":100},[],{"trials":3664,"activeCount":100},[],{"trials":3666,"activeCount":100},[],{"intervention":3660,"totalTrials":126,"cells":3668},{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3673,"PHASE3":3679,"PHASE4":3681,"NA":3683},{"trials":3670,"activeCount":100},[],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[3675],{"nctId":3653,"briefTitle":3654,"status":156,"phases":3676,"primaryCompletion":1411,"completion":1411,"start":3656,"enrollment":16,"conditions":3677,"interventions":3678},[89],[24,3658],[3644,3660],{"trials":3680,"activeCount":100},[],{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[],{"intervention":3686,"totalTrials":126,"cells":3687},"Paroxetine",{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3705,"PHASE4":3707,"NA":3709},{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[3694],{"nctId":3695,"briefTitle":3696,"status":156,"phases":3697,"primaryCompletion":3698,"completion":3699,"start":3700,"enrollment":11,"conditions":3701,"interventions":3704},"NCT03274752","Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction",[89],"2021-01-01","2022-03-01","2017-10-26",[3702,3703],"Cardiac Remodeling","Myocardial Infarction",[3686],{"trials":3706,"activeCount":100},[],{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"intervention":3712,"totalTrials":126,"cells":3713},"PADMA 28",{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3718,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3715,"activeCount":100},[],{"trials":3717,"activeCount":100},[],{"trials":3719,"activeCount":100},[3720],{"nctId":3721,"briefTitle":3722,"status":156,"phases":3723,"primaryCompletion":3724,"completion":3724,"start":3725,"enrollment":1266,"conditions":3726,"interventions":3727},"NCT01581034","Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery Disease",[89],"2013-05","2012-04",[15],[3712],{"trials":3729,"activeCount":100},[],{"trials":3731,"activeCount":100},[],{"trials":3733,"activeCount":100},[],{"intervention":2917,"totalTrials":126,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3746,"PHASE4":3748,"NA":3750},{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[],{"trials":3741,"activeCount":100},[3742],{"nctId":2909,"briefTitle":2910,"status":156,"phases":3743,"primaryCompletion":2912,"completion":135,"start":2913,"enrollment":2914,"conditions":3744,"interventions":3745},[89],[632],[2907,2879,2917],{"trials":3747,"activeCount":100},[],{"trials":3749,"activeCount":100},[],{"trials":3751,"activeCount":100},[],{"intervention":3753,"totalTrials":126,"cells":3754},"Intravitreal ranibizumab with photodynamic therapy",{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[],{"trials":3760,"activeCount":100},[3761],{"nctId":3762,"briefTitle":3763,"status":156,"phases":3764,"primaryCompletion":3765,"completion":2031,"start":3766,"enrollment":1201,"conditions":3767,"interventions":3768},"NCT00413829","Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)",[89],"2007-05","2006-10",[2157],[3753],{"trials":3770,"activeCount":100},[],{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"intervention":3776,"totalTrials":126,"cells":3777},"Mepolizumab",{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3793,"PHASE4":3795,"NA":3797},{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[],{"trials":3783,"activeCount":100},[3784],{"nctId":3785,"briefTitle":3786,"status":156,"phases":3787,"primaryCompletion":3788,"completion":3788,"start":3789,"enrollment":2252,"conditions":3790,"interventions":3792},"NCT01705795","Anti-IL-5 Therapy in Bullous Pemphigoid (BP)",[89],"2017-01-31","2013-02-13",[3791],"Pemphigoid, Bullous",[3776],{"trials":3794,"activeCount":100},[],{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"intervention":3800,"totalTrials":126,"cells":3801},"Ivermectin 1% cream",{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3803,"activeCount":100},[],{"trials":3805,"activeCount":100},[],{"trials":3807,"activeCount":100},[3808],{"nctId":3809,"briefTitle":3810,"status":156,"phases":3811,"primaryCompletion":3812,"completion":3812,"start":3813,"enrollment":1483,"conditions":3814,"interventions":3816},"NCT06033352","Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea",[89],"2024-11-01","2023-09-12",[3815],"Rosacea",[3800],{"trials":3818,"activeCount":100},[],{"trials":3820,"activeCount":100},[],{"trials":3822,"activeCount":100},[],{"intervention":3824,"totalTrials":126,"cells":3825},"Clobetasol propionate 0.05%",{"EARLY_PHASE1":3826,"PHASE1":3828,"PHASE2":3830,"PHASE3":3842,"PHASE4":3844,"NA":3846},{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[],{"trials":3831,"activeCount":100},[3832],{"nctId":3833,"briefTitle":3834,"status":1041,"phases":3835,"primaryCompletion":3836,"completion":3836,"start":2690,"enrollment":3837,"conditions":3838,"interventions":3840},"NCT01126255","Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus",[89],"2014-07",37,[3839],"Vulvar Lichen Sclerosus",[3824,3841],"Progesterone 8%",{"trials":3843,"activeCount":100},[],{"trials":3845,"activeCount":100},[],{"trials":3847,"activeCount":100},[],{"intervention":3841,"totalTrials":126,"cells":3849},{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3860,"PHASE4":3862,"NA":3864},{"trials":3851,"activeCount":100},[],{"trials":3853,"activeCount":100},[],{"trials":3855,"activeCount":100},[3856],{"nctId":3833,"briefTitle":3834,"status":1041,"phases":3857,"primaryCompletion":3836,"completion":3836,"start":2690,"enrollment":3837,"conditions":3858,"interventions":3859},[89],[3839],[3824,3841],{"trials":3861,"activeCount":100},[],{"trials":3863,"activeCount":100},[],{"trials":3865,"activeCount":100},[],{"intervention":3867,"totalTrials":126,"cells":3868},"Terlipressin",{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3873,"PHASE3":3885,"PHASE4":3887,"NA":3889},{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[3875],{"nctId":3876,"briefTitle":3877,"status":1041,"phases":3878,"primaryCompletion":3879,"completion":3879,"start":3880,"enrollment":1426,"conditions":3881,"interventions":3884},"NCT01921985","Terlipressin Administration in Patients Undergoing Major Liver Resection",[89],"2018-03","2013-11",[3882,3883],"Liver Resection","Liver Failure",[3867],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[],{"trials":3890,"activeCount":100},[],{"intervention":3892,"totalTrials":96,"cells":3893},"Epacadostat",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3920,"PHASE3":3922,"PHASE4":3924,"NA":3926},{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":100},[3898,3911],{"nctId":3899,"briefTitle":3900,"status":2756,"phases":3901,"primaryCompletion":3902,"completion":3903,"start":3904,"enrollment":100,"conditions":3905,"interventions":3908},"NCT03491579","Epacadostat, Cladribine and Cytarabine (ECC) in AML",[88],"2019-09","2019-10","2018-12",[3906,3907],"AML","Relapse",[3892,3909,3910],"Cladribine","Cytarabine",{"nctId":3912,"briefTitle":3913,"status":2756,"phases":3914,"primaryCompletion":3915,"completion":3903,"start":1626,"enrollment":100,"conditions":3916,"interventions":3917},"NCT03444649","Epacadostat, Idarubicin and Cytarabine (EIC) in AML",[88],"2019-08",[3906],[3892,3918,3910,3919],"Idarubicin","Daunorubicin",{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[],{"trials":3927,"activeCount":100},[],{"intervention":3910,"totalTrials":96,"cells":3929},{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3942,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3931,"activeCount":100},[],{"trials":3933,"activeCount":100},[3934,3938],{"nctId":3899,"briefTitle":3900,"status":2756,"phases":3935,"primaryCompletion":3902,"completion":3903,"start":3904,"enrollment":100,"conditions":3936,"interventions":3937},[88],[3906,3907],[3892,3909,3910],{"nctId":3912,"briefTitle":3913,"status":2756,"phases":3939,"primaryCompletion":3915,"completion":3903,"start":1626,"enrollment":100,"conditions":3940,"interventions":3941},[88],[3906],[3892,3918,3910,3919],{"trials":3943,"activeCount":100},[],{"trials":3945,"activeCount":100},[],{"trials":3947,"activeCount":100},[],{"trials":3949,"activeCount":100},[],{"intervention":3909,"totalTrials":126,"cells":3951},{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3960,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3953,"activeCount":100},[],{"trials":3955,"activeCount":100},[3956],{"nctId":3899,"briefTitle":3900,"status":2756,"phases":3957,"primaryCompletion":3902,"completion":3903,"start":3904,"enrollment":100,"conditions":3958,"interventions":3959},[88],[3906,3907],[3892,3909,3910],{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"intervention":3918,"totalTrials":126,"cells":3969},{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3978,"PHASE3":3980,"PHASE4":3982,"NA":3984},{"trials":3971,"activeCount":100},[],{"trials":3973,"activeCount":100},[3974],{"nctId":3912,"briefTitle":3913,"status":2756,"phases":3975,"primaryCompletion":3915,"completion":3903,"start":1626,"enrollment":100,"conditions":3976,"interventions":3977},[88],[3906],[3892,3918,3910,3919],{"trials":3979,"activeCount":100},[],{"trials":3981,"activeCount":100},[],{"trials":3983,"activeCount":100},[],{"trials":3985,"activeCount":100},[],{"intervention":3919,"totalTrials":126,"cells":3987},{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[3992],{"nctId":3912,"briefTitle":3913,"status":2756,"phases":3993,"primaryCompletion":3915,"completion":3903,"start":1626,"enrollment":100,"conditions":3994,"interventions":3995},[88],[3906],[3892,3918,3910,3919],{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[],{"trials":4001,"activeCount":100},[],{"trials":4003,"activeCount":100},[],{"intervention":2998,"totalTrials":126,"cells":4005},{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[4010],{"nctId":2989,"briefTitle":2990,"status":156,"phases":4011,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":2994,"conditions":4012,"interventions":4013},[88],[2996],[2998,2982],{"trials":4015,"activeCount":100},[],{"trials":4017,"activeCount":100},[],{"trials":4019,"activeCount":100},[],{"trials":4021,"activeCount":100},[],{"intervention":2894,"totalTrials":126,"cells":4023},{"EARLY_PHASE1":4024,"PHASE1":4026,"PHASE2":4032,"PHASE3":4034,"PHASE4":4036,"NA":4038},{"trials":4025,"activeCount":100},[],{"trials":4027,"activeCount":100},[4028],{"nctId":2886,"briefTitle":2887,"status":2756,"phases":4029,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":100,"conditions":4030,"interventions":4031},[88],[2892],[2894,2895,2879],{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":100},[],{"trials":4037,"activeCount":100},[],{"trials":4039,"activeCount":100},[],{"intervention":2895,"totalTrials":126,"cells":4041},{"EARLY_PHASE1":4042,"PHASE1":4044,"PHASE2":4050,"PHASE3":4052,"PHASE4":4054,"NA":4056},{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[4046],{"nctId":2886,"briefTitle":2887,"status":2756,"phases":4047,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":100,"conditions":4048,"interventions":4049},[88],[2892],[2894,2895,2879],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"intervention":4059,"totalTrials":126,"cells":4060},"Daptomycin",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4073,"PHASE3":4075,"PHASE4":4077,"NA":4079},{"trials":4062,"activeCount":100},[],{"trials":4064,"activeCount":100},[4065],{"nctId":4066,"briefTitle":4067,"status":1041,"phases":4068,"primaryCompletion":4069,"completion":4069,"start":3725,"enrollment":126,"conditions":4070,"interventions":4072},"NCT01522105","Daptomycin in Pediatric Patients With Bacterial Meningitis",[88],"2018-06-30",[4071],"Meningitis",[4059],{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[],{"trials":4080,"activeCount":100},[],{"intervention":4082,"totalTrials":126,"cells":4083},"N,N-dimethyltryptamine (DMT) + harmine",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4098,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4085,"activeCount":100},[],{"trials":4087,"activeCount":100},[4088],{"nctId":4089,"briefTitle":4090,"status":156,"phases":4091,"primaryCompletion":4092,"completion":4093,"start":4094,"enrollment":1413,"conditions":4095,"interventions":4097},"NCT06252506","Molecular Imaging Study of Harmine\u002FDMT: a Basic Research Approach",[88],"2025-02-17","2025-03-05","2024-01-22",[4096],"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine",[4082],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[],{"intervention":4107,"totalTrials":126,"cells":4108},"HDM201",{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4123,"PHASE3":4125,"PHASE4":4127,"NA":4129},{"trials":4110,"activeCount":100},[],{"trials":4112,"activeCount":100},[4113],{"nctId":4114,"briefTitle":4115,"status":1041,"phases":4116,"primaryCompletion":4117,"completion":4117,"start":4118,"enrollment":96,"conditions":4119,"interventions":4121},"NCT04496999","HDM201 and Midostaurin (HDMM) in Relapsed\u002FRefractory AML With FLT3mut and TP53wt.",[88],"2022-09-09","2020-07-13",[4120],"AML, Adult",[4107,4122],"Midostaurin",{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[],{"trials":4130,"activeCount":100},[],{"intervention":4122,"totalTrials":126,"cells":4132},{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4141,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4134,"activeCount":100},[],{"trials":4136,"activeCount":100},[4137],{"nctId":4114,"briefTitle":4115,"status":1041,"phases":4138,"primaryCompletion":4117,"completion":4117,"start":4118,"enrollment":96,"conditions":4139,"interventions":4140},[88],[4120],[4107,4122],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[],{"trials":4148,"activeCount":100},[],{"intervention":4150,"totalTrials":126,"cells":4151},"Micro-glucagon",{"EARLY_PHASE1":4152,"PHASE1":4166,"PHASE2":4168,"PHASE3":4170,"PHASE4":4172,"NA":4174},{"trials":4153,"activeCount":100},[4154],{"nctId":4155,"briefTitle":4156,"status":2756,"phases":4157,"primaryCompletion":4158,"completion":4159,"start":4160,"enrollment":100,"conditions":4161,"interventions":4164},"NCT04192019","Micro Glucagon During Exercise in Type 1 Diabetes",[87],"2024-04","2024-06","2023-04",[4162,4163],"Type 1 Diabetes","Hypoglycemia",[4150,4165],"Mini-glucagon",{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":100},[],{"trials":4173,"activeCount":100},[],{"trials":4175,"activeCount":100},[],{"intervention":4165,"totalTrials":126,"cells":4177},{"EARLY_PHASE1":4178,"PHASE1":4184,"PHASE2":4186,"PHASE3":4188,"PHASE4":4190,"NA":4192},{"trials":4179,"activeCount":100},[4180],{"nctId":4155,"briefTitle":4156,"status":2756,"phases":4181,"primaryCompletion":4158,"completion":4159,"start":4160,"enrollment":100,"conditions":4182,"interventions":4183},[87],[4162,4163],[4150,4165],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[],{"trials":4191,"activeCount":100},[],{"trials":4193,"activeCount":100},[],{"intervention":4195,"totalTrials":126,"cells":4196},"Indocyanine Green",{"EARLY_PHASE1":4197,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4217,"NA":4219},{"trials":4198,"activeCount":100},[4199],{"nctId":4200,"briefTitle":4201,"status":156,"phases":4202,"primaryCompletion":4203,"completion":4204,"start":4205,"enrollment":2820,"conditions":4206,"interventions":4210},"NCT03850158","Diagnostic Value of ICG in Endometriosis",[87],"2019-11","2019-12","2017-01",[185,4207,4208,4209],"Laparoscopy","Near Infrared Fluorescence Imaging","Indocyanine Green (ICG)",[4195],{"trials":4212,"activeCount":100},[],{"trials":4214,"activeCount":100},[],{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[],{"trials":4220,"activeCount":100},[],{"intervention":164,"totalTrials":1333,"cells":4222},{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4227,"PHASE3":4229,"PHASE4":4231,"NA":4259},{"trials":4224,"activeCount":100},[],{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":100},[],{"trials":4230,"activeCount":100},[],{"trials":4232,"activeCount":100},[4233,4237,4247],{"nctId":154,"briefTitle":155,"status":156,"phases":4234,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":4235,"interventions":4236},[91],[27,162,163,140,164],[140,164],{"nctId":4238,"briefTitle":4239,"status":156,"phases":4240,"primaryCompletion":4241,"completion":4242,"start":4243,"enrollment":1764,"conditions":4244,"interventions":4246},"NCT04662177","Co-administration of Dexmedetomidine in Carotid Endarterectomy (CEA)",[91],"2020-10-16","2020-12-04","2018-11-21",[4245],"Carotid Stenosis",[164],{"nctId":4248,"briefTitle":4249,"status":2756,"phases":4250,"primaryCompletion":4251,"completion":4252,"start":4253,"enrollment":100,"conditions":4254,"interventions":4257},"NCT03399838","Comparing in Dexmedetomidine With po\u002Fpr Midazolam for Procedural Sedation in the Pediatric Emergency Department",[91],"2024-07-31","2024-08-31","2023-08",[4255,4256],"Procedural Anxiety","Emergencies",[164,4258],"Midazolam",{"trials":4260,"activeCount":100},[4261,4272],{"nctId":4262,"briefTitle":4263,"status":156,"phases":4264,"primaryCompletion":4265,"completion":4266,"start":4267,"enrollment":562,"conditions":4268,"interventions":4270},"NCT04076826","Adjunctive Sedation With Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy",[92],"2022-06-17","2022-07-08","2019-09-01",[4269],"Sepsis-Associated Encephalopathy",[164,4271],"Propofol or Midazolam",{"nctId":4273,"briefTitle":4274,"status":156,"phases":4275,"primaryCompletion":4276,"completion":4276,"start":4277,"enrollment":25,"conditions":4278,"interventions":4282},"NCT00641563","Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)",[92],"2004-06","2004-03",[4279,4280,4281],"Conscious Sedation","Deep Sedation","Critical Care",[164,4258,4283],"Remifentanil",{"intervention":177,"totalTrials":141,"cells":4285},{"EARLY_PHASE1":4286,"PHASE1":4288,"PHASE2":4290,"PHASE3":4303,"PHASE4":4305,"NA":4311},{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[4292],{"nctId":4293,"briefTitle":4294,"status":1041,"phases":4295,"primaryCompletion":4296,"completion":3725,"start":4297,"enrollment":4298,"conditions":4299,"interventions":4302},"NCT01574014","Glucocorticoid Treatment for Social Phobia",[89],"2012-03","2009-07",66,[4300,4301],"Phobic Disorders","Phobias",[177],{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[4307],{"nctId":167,"briefTitle":168,"status":156,"phases":4308,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":4309,"interventions":4310},[91],[15,174],[176,140,177,178],{"trials":4312,"activeCount":100},[4313],{"nctId":4314,"briefTitle":4315,"status":1041,"phases":4316,"primaryCompletion":1349,"completion":1349,"start":1894,"enrollment":16,"conditions":4317,"interventions":4322},"NCT02360046","The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism",[92],[4318,177,4319,4320,4321],"Hypopituitarism","Lipids","Fatty Acids, Nonesterified","Insulin Sensitivity",[177],{"intervention":4324,"totalTrials":96,"cells":4325},"Metformin",{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4332,"PHASE4":4334,"NA":4336},{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[],{"trials":4333,"activeCount":100},[],{"trials":4335,"activeCount":100},[],{"trials":4337,"activeCount":100},[4338,4348],{"nctId":4339,"briefTitle":4340,"status":2074,"phases":4341,"primaryCompletion":4253,"completion":4342,"start":4343,"enrollment":4344,"conditions":4345,"interventions":4347},"NCT04930471","Steroid and Behaviour Changes Under Metformin",[],"2023-12","2021-06",45,[4346],"Autistic Disorder",[4324],{"nctId":4349,"briefTitle":4350,"status":156,"phases":4351,"primaryCompletion":4352,"completion":4353,"start":4354,"enrollment":1413,"conditions":4355,"interventions":4358},"NCT03510390","Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation",[92],"2021-09-15","2021-11-15","2018-06-13",[4356,4357],"Head and Neck Cancer","Oral Cavity Squamous Cell Carcinoma",[4324],{"intervention":4360,"totalTrials":96,"cells":4361},"Sodium thiosulfate",{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4373,"PHASE3":4375,"PHASE4":4377,"NA":4379},{"trials":4363,"activeCount":100},[],{"trials":4365,"activeCount":100},[4366],{"nctId":4367,"briefTitle":4368,"status":2756,"phases":4369,"primaryCompletion":4370,"completion":4204,"start":3904,"enrollment":100,"conditions":4371,"interventions":4372},"NCT02624479","Pharmacokinetic Study to Investigate the Bioavailability and Tolerability of 3 Oral Formulations of Sodium Thiosulfate",[88],"2019-05",[34],[4360],{"trials":4374,"activeCount":100},[],{"trials":4376,"activeCount":100},[],{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[4381],{"nctId":4382,"briefTitle":4383,"status":156,"phases":4384,"primaryCompletion":4385,"completion":4385,"start":4386,"enrollment":4387,"conditions":4388,"interventions":4390},"NCT01008631","The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers",[92],"2010-08","2009-09",19,[4389],"Renal Failure",[4360],{"intervention":4392,"totalTrials":96,"cells":4393},"Carbetocin",{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4398,"PHASE3":4400,"PHASE4":4402,"NA":4414},{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[],{"trials":4403,"activeCount":100},[4404],{"nctId":4405,"briefTitle":4406,"status":2074,"phases":4407,"primaryCompletion":3296,"completion":4408,"start":4409,"enrollment":4410,"conditions":4411,"interventions":4413},"NCT02642263","Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain",[91],"2022-01","2019-02-01",78,[4412],"Cesarean Delivery",[4392],{"trials":4415,"activeCount":100},[4416],{"nctId":4417,"briefTitle":4418,"status":156,"phases":4419,"primaryCompletion":1893,"completion":1893,"start":4420,"enrollment":9,"conditions":4421,"interventions":4424},"NCT01918475","Analgesic Effect of Oxytocin Receptor Modulation",[92],"2013-07",[24,4422,4423],"Hyperalgesia","Central Sensitization",[4392],{"intervention":4258,"totalTrials":96,"cells":4426},{"EARLY_PHASE1":4427,"PHASE1":4429,"PHASE2":4431,"PHASE3":4433,"PHASE4":4435,"NA":4441},{"trials":4428,"activeCount":100},[],{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[4437],{"nctId":4248,"briefTitle":4249,"status":2756,"phases":4438,"primaryCompletion":4251,"completion":4252,"start":4253,"enrollment":100,"conditions":4439,"interventions":4440},[91],[4255,4256],[164,4258],{"trials":4442,"activeCount":100},[4443],{"nctId":4273,"briefTitle":4274,"status":156,"phases":4444,"primaryCompletion":4276,"completion":4276,"start":4277,"enrollment":25,"conditions":4445,"interventions":4446},[92],[4279,4280,4281],[164,4258,4283],{"intervention":4448,"totalTrials":126,"cells":4449},"fluvastatin",{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4454,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4451,"activeCount":100},[],{"trials":4453,"activeCount":100},[],{"trials":4455,"activeCount":100},[],{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[4462],{"nctId":4463,"briefTitle":4464,"status":156,"phases":4465,"enrollment":858,"conditions":4466,"interventions":4468},"NCT00465322","Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation",[],[4467],"Drug-Interactions",[4448],{"intervention":4470,"totalTrials":126,"cells":4471},"Triple cream",{"EARLY_PHASE1":4472,"PHASE1":4474,"PHASE2":4476,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4473,"activeCount":100},[],{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[],{"trials":4481,"activeCount":100},[],{"trials":4483,"activeCount":100},[4484],{"nctId":4485,"briefTitle":4486,"status":156,"phases":4487,"primaryCompletion":4488,"completion":4488,"start":4489,"enrollment":4298,"conditions":4490,"interventions":4493},"NCT05165524","Brightening Cream and Lasers in Post-sclerotherapy Hyperpigmentation",[92],"2025-01-14","2022-03-03",[4491,4492],"Hyperpigmentation","Varicosis",[4470],{"intervention":4495,"totalTrials":126,"cells":4496},"Growth hormone replacement therapy in growth hormone deficient patients only.",{"EARLY_PHASE1":4497,"PHASE1":4499,"PHASE2":4501,"PHASE3":4503,"PHASE4":4505,"NA":4507},{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":100},[4509],{"nctId":4510,"briefTitle":4511,"status":156,"phases":4512,"primaryCompletion":4297,"completion":4513,"start":4514,"enrollment":4515,"conditions":4516,"interventions":4518},"NCT00491582","The Effects of Growth Hormone (GH) on Lipid Depots",[92],"2013-06","2007-07",34,[4517],"Growth Hormone Deficiency",[4495],{"intervention":4520,"totalTrials":126,"cells":4521},"catheter-directed thrombolysis",{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4528,"PHASE4":4530,"NA":4532},{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[],{"trials":4533,"activeCount":100},[4534],{"nctId":4535,"briefTitle":4536,"status":156,"phases":4537,"primaryCompletion":4538,"completion":158,"start":4539,"enrollment":2445,"conditions":4540,"interventions":4542},"NCT03218410","Surgical Pulmonary Embolectomy Versus Catheter-directed Thrombolysis in the Treatment of Pulmonary Embolism: A Non-inferiority Study",[92],"2020-06-30","2015-10-01",[4541],"Acute Pulmonary Embolism (PE)",[4520],{"intervention":4544,"totalTrials":126,"cells":4545},"Syntocinon-Spray",{"EARLY_PHASE1":4546,"PHASE1":4548,"PHASE2":4550,"PHASE3":4552,"PHASE4":4554,"NA":4556},{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[],{"trials":4551,"activeCount":100},[],{"trials":4553,"activeCount":100},[],{"trials":4555,"activeCount":100},[],{"trials":4557,"activeCount":100},[4558],{"nctId":4559,"briefTitle":4560,"status":1041,"phases":4561,"primaryCompletion":943,"completion":943,"start":1441,"enrollment":4562,"conditions":4563,"interventions":4565},"NCT01938911","The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension",[92],16,[4564],"Essential Hypertension",[4544],{"intervention":4567,"totalTrials":126,"cells":4568},"Ozanimod",{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4579},{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[4581],{"nctId":4582,"briefTitle":4583,"status":2074,"phases":4584,"primaryCompletion":4585,"completion":4585,"start":4586,"enrollment":4587,"conditions":4588,"interventions":4590},"NCT05702879","Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success",[],"2025-01-31","2023-09-06",240,[4589],"Ulcerative Colitis",[4567,4591,1059,4592,4593],"TNF Inhibitor","Vedolizumab","Ustekinumab",{"intervention":4591,"totalTrials":126,"cells":4595},{"EARLY_PHASE1":4596,"PHASE1":4598,"PHASE2":4600,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4597,"activeCount":100},[],{"trials":4599,"activeCount":100},[],{"trials":4601,"activeCount":100},[],{"trials":4603,"activeCount":100},[],{"trials":4605,"activeCount":100},[],{"trials":4607,"activeCount":100},[4608],{"nctId":4582,"briefTitle":4583,"status":2074,"phases":4609,"primaryCompletion":4585,"completion":4585,"start":4586,"enrollment":4587,"conditions":4610,"interventions":4611},[],[4589],[4567,4591,1059,4592,4593],{"intervention":1059,"totalTrials":126,"cells":4613},{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4618,"PHASE3":4620,"PHASE4":4622,"NA":4624},{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"trials":4619,"activeCount":100},[],{"trials":4621,"activeCount":100},[],{"trials":4623,"activeCount":100},[],{"trials":4625,"activeCount":100},[4626],{"nctId":4582,"briefTitle":4583,"status":2074,"phases":4627,"primaryCompletion":4585,"completion":4585,"start":4586,"enrollment":4587,"conditions":4628,"interventions":4629},[],[4589],[4567,4591,1059,4592,4593],{"intervention":4592,"totalTrials":126,"cells":4631},{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4636,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":100},[],{"trials":4639,"activeCount":100},[],{"trials":4641,"activeCount":100},[],{"trials":4643,"activeCount":100},[4644],{"nctId":4582,"briefTitle":4583,"status":2074,"phases":4645,"primaryCompletion":4585,"completion":4585,"start":4586,"enrollment":4587,"conditions":4646,"interventions":4647},[],[4589],[4567,4591,1059,4592,4593],{"intervention":4593,"totalTrials":126,"cells":4649},{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4651,"activeCount":100},[],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":100},[4662],{"nctId":4582,"briefTitle":4583,"status":2074,"phases":4663,"primaryCompletion":4585,"completion":4585,"start":4586,"enrollment":4587,"conditions":4664,"interventions":4665},[],[4589],[4567,4591,1059,4592,4593],{"intervention":4667,"totalTrials":126,"cells":4668},"Ureteral injection of Indocyanine Green Powder",{"EARLY_PHASE1":4669,"PHASE1":4671,"PHASE2":4673,"PHASE3":4675,"PHASE4":4677,"NA":4679},{"trials":4670,"activeCount":100},[],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[4681],{"nctId":4682,"briefTitle":4683,"status":2074,"phases":4684,"primaryCompletion":54,"completion":54,"start":4685,"enrollment":11,"conditions":4686,"interventions":4691},"NCT05206279","ICG for Visualization of the Ureters in DIE",[92],"2023-06-26",[4687,4688,4689,4690,4207],"Visualization of Ureters in Gynecological Surgery","Deep Infiltrative Endometriosis","ICG (Indocyanine Green)","Near Infrared Imaging",[4667],{"intervention":4693,"totalTrials":126,"cells":4694},"Bupivacain 0.125%",{"EARLY_PHASE1":4695,"PHASE1":4697,"PHASE2":4699,"PHASE3":4701,"PHASE4":4703,"NA":4705},{"trials":4696,"activeCount":100},[],{"trials":4698,"activeCount":100},[],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[],{"trials":4704,"activeCount":100},[],{"trials":4706,"activeCount":100},[4707],{"nctId":4708,"briefTitle":4709,"status":156,"phases":4710,"primaryCompletion":1043,"completion":1043,"start":4711,"enrollment":4712,"conditions":4713,"interventions":4717},"NCT01220362","Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study",[92],"2010-10",40,[4714,4715,4716],"Analgesia, Epidural","Urodynamics","Urinary Retention",[4693,4718],"Bupivacain 0.125%\u002FFentanyl 2mcg\u002Fml",{"intervention":4718,"totalTrials":126,"cells":4720},{"EARLY_PHASE1":4721,"PHASE1":4723,"PHASE2":4725,"PHASE3":4727,"PHASE4":4729,"NA":4731},{"trials":4722,"activeCount":100},[],{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"trials":4730,"activeCount":100},[],{"trials":4732,"activeCount":100},[4733],{"nctId":4708,"briefTitle":4709,"status":156,"phases":4734,"primaryCompletion":1043,"completion":1043,"start":4711,"enrollment":4712,"conditions":4735,"interventions":4736},[92],[4714,4715,4716],[4693,4718],{"intervention":4271,"totalTrials":126,"cells":4738},{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4743,"PHASE3":4745,"PHASE4":4747,"NA":4749},{"trials":4740,"activeCount":100},[],{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[],{"trials":4748,"activeCount":100},[],{"trials":4750,"activeCount":100},[4751],{"nctId":4262,"briefTitle":4263,"status":156,"phases":4752,"primaryCompletion":4265,"completion":4266,"start":4267,"enrollment":562,"conditions":4753,"interventions":4754},[92],[4269],[164,4271],{"intervention":4756,"totalTrials":126,"cells":4757},"THC 9-d-tetra hydro cannabinol",{"EARLY_PHASE1":4758,"PHASE1":4760,"PHASE2":4762,"PHASE3":4764,"PHASE4":4766,"NA":4768},{"trials":4759,"activeCount":100},[],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[],{"trials":4767,"activeCount":100},[],{"trials":4769,"activeCount":100},[4770],{"nctId":4771,"briefTitle":4772,"status":1041,"phases":4773,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":1102,"conditions":4777,"interventions":4780},"NCT00695487","Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?",[92],"2010-12","2011-12","2008-07",[4778,4779],"Nausea","Vomiting",[4756],{"intervention":4782,"totalTrials":126,"cells":4783},"Standard insulin therapy",{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4788,"PHASE3":4790,"PHASE4":4792,"NA":4794},{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[],{"trials":4791,"activeCount":100},[],{"trials":4793,"activeCount":100},[],{"trials":4795,"activeCount":100},[4796],{"nctId":4797,"briefTitle":4798,"status":156,"phases":4799,"primaryCompletion":4800,"completion":4800,"start":4801,"enrollment":4344,"conditions":4802,"interventions":4808},"NCT04361799","Perioperative Closed-loop Glucose Control",[92],"2021-09-02","2020-09-25",[4803,4804,4805,4806,4807],"Perioperative Hyperglycaemia","Insulin Therapy","Elective Surgery","Closed-Loop Glucose Control","Artificial Pancreas",[4782],{"intervention":4810,"totalTrials":126,"cells":4811},"Nitrous oxide",{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4813,"activeCount":100},[],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"trials":4821,"activeCount":100},[],{"trials":4823,"activeCount":100},[4824],{"nctId":4825,"briefTitle":4826,"status":2074,"phases":4827,"primaryCompletion":682,"completion":682,"start":4828,"enrollment":858,"conditions":4829,"interventions":4833},"NCT05510141","Virtual Reality Games in Pediatric Surgery",[92],"2022-08-24",[4830,4831,4832],"Analgesia","Surgical Procedure, Unspecified","Immersion",[4810],{"intervention":4835,"totalTrials":126,"cells":4836},"Oxygen 70l\u002Fmin",{"EARLY_PHASE1":4837,"PHASE1":4839,"PHASE2":4841,"PHASE3":4843,"PHASE4":4845,"NA":4847},{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[],{"trials":4842,"activeCount":100},[],{"trials":4844,"activeCount":100},[],{"trials":4846,"activeCount":100},[],{"trials":4848,"activeCount":100},[4849],{"nctId":4850,"briefTitle":4851,"status":156,"phases":4852,"primaryCompletion":4853,"completion":4853,"start":4854,"enrollment":4855,"conditions":4856,"interventions":4857},"NCT03478774","Physiology Regarding Apnoeic Oxygenation During Nasal Cannula Therapy at Different Flow Rates",[92],"2019-12-31","2018-03-25",125,[998],[4835,4858,4859,4860],"Oxygen 10 l\u002Fmin","Oxygen 2l\u002Fmin","oxygen 0.25l\u002Fmin",{"intervention":4858,"totalTrials":126,"cells":4862},{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4869,"PHASE4":4871,"NA":4873},{"trials":4864,"activeCount":100},[],{"trials":4866,"activeCount":100},[],{"trials":4868,"activeCount":100},[],{"trials":4870,"activeCount":100},[],{"trials":4872,"activeCount":100},[],{"trials":4874,"activeCount":100},[4875],{"nctId":4850,"briefTitle":4851,"status":156,"phases":4876,"primaryCompletion":4853,"completion":4853,"start":4854,"enrollment":4855,"conditions":4877,"interventions":4878},[92],[998],[4835,4858,4859,4860],{"intervention":4859,"totalTrials":126,"cells":4880},{"EARLY_PHASE1":4881,"PHASE1":4883,"PHASE2":4885,"PHASE3":4887,"PHASE4":4889,"NA":4891},{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[],{"trials":4886,"activeCount":100},[],{"trials":4888,"activeCount":100},[],{"trials":4890,"activeCount":100},[],{"trials":4892,"activeCount":100},[4893],{"nctId":4850,"briefTitle":4851,"status":156,"phases":4894,"primaryCompletion":4853,"completion":4853,"start":4854,"enrollment":4855,"conditions":4895,"interventions":4896},[92],[998],[4835,4858,4859,4860],{"intervention":4860,"totalTrials":126,"cells":4898},{"EARLY_PHASE1":4899,"PHASE1":4901,"PHASE2":4903,"PHASE3":4905,"PHASE4":4907,"NA":4909},{"trials":4900,"activeCount":100},[],{"trials":4902,"activeCount":100},[],{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[4911],{"nctId":4850,"briefTitle":4851,"status":156,"phases":4912,"primaryCompletion":4853,"completion":4853,"start":4854,"enrollment":4855,"conditions":4913,"interventions":4914},[92],[998],[4835,4858,4859,4860],{"intervention":4916,"totalTrials":126,"cells":4917},"Early treatment with Rivaroxaban",{"EARLY_PHASE1":4918,"PHASE1":4920,"PHASE2":4922,"PHASE3":4924,"PHASE4":4926,"NA":4928},{"trials":4919,"activeCount":100},[],{"trials":4921,"activeCount":100},[],{"trials":4923,"activeCount":100},[],{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[],{"trials":4929,"activeCount":100},[4930],{"nctId":4931,"briefTitle":4932,"status":156,"phases":4933,"primaryCompletion":4934,"completion":4935,"start":4936,"enrollment":4937,"conditions":4938,"interventions":4940},"NCT03148457","Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial",[92],"2022-12-21","2023-05-24","2017-11-06",2013,[4939],"Ischaemic Stroke",[4916,4941],"Late treatment with Rivaroxaban",{"intervention":4941,"totalTrials":126,"cells":4943},{"EARLY_PHASE1":4944,"PHASE1":4946,"PHASE2":4948,"PHASE3":4950,"PHASE4":4952,"NA":4954},{"trials":4945,"activeCount":100},[],{"trials":4947,"activeCount":100},[],{"trials":4949,"activeCount":100},[],{"trials":4951,"activeCount":100},[],{"trials":4953,"activeCount":100},[],{"trials":4955,"activeCount":100},[4956],{"nctId":4931,"briefTitle":4932,"status":156,"phases":4957,"primaryCompletion":4934,"completion":4935,"start":4936,"enrollment":4937,"conditions":4958,"interventions":4959},[92],[4939],[4916,4941],{"intervention":4961,"totalTrials":126,"cells":4962},"Furosemide-Fludrocortisone-Test",{"EARLY_PHASE1":4963,"PHASE1":4965,"PHASE2":4967,"PHASE3":4969,"PHASE4":4971,"NA":4973},{"trials":4964,"activeCount":100},[],{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":100},[],{"trials":4974,"activeCount":100},[4975],{"nctId":4976,"briefTitle":4977,"status":156,"phases":4978,"primaryCompletion":4979,"completion":4980,"start":2615,"enrollment":4981,"conditions":4982,"interventions":4985},"NCT01690039","Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis",[],"2016-12-31","2017-05-12",170,[4983,542,4984],"Acidosis, Renal Tubular","Vacuolar Proton-Translocating ATPases",[4961],{"intervention":4987,"totalTrials":126,"cells":4988},"Filgrastim",{"EARLY_PHASE1":4989,"PHASE1":4991,"PHASE2":4993,"PHASE3":4995,"PHASE4":4997,"NA":4999},{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[],{"trials":4996,"activeCount":100},[],{"trials":4998,"activeCount":100},[],{"trials":5000,"activeCount":100},[5001],{"nctId":5002,"briefTitle":5003,"status":156,"phases":5004,"primaryCompletion":5005,"completion":5005,"start":5006,"enrollment":11,"conditions":5007,"interventions":5008},"NCT00596479","Filgrastim for the Promotion of Collateral Growth in Patients With CAD",[92],"2007-12","2004-11",[15],[4987],{"intervention":5010,"totalTrials":126,"cells":5011},"Ivabradine",{"EARLY_PHASE1":5012,"PHASE1":5014,"PHASE2":5016,"PHASE3":5018,"PHASE4":5020,"NA":5022},{"trials":5013,"activeCount":100},[],{"trials":5015,"activeCount":100},[],{"trials":5017,"activeCount":100},[],{"trials":5019,"activeCount":100},[],{"trials":5021,"activeCount":100},[],{"trials":5023,"activeCount":100},[5024],{"nctId":5025,"briefTitle":5026,"status":156,"phases":5027,"primaryCompletion":1372,"completion":1372,"start":5028,"enrollment":5029,"conditions":5030,"interventions":5031},"NCT01039389","Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease",[92],"2009-10",43,[15],[5010],{"intervention":5033,"totalTrials":126,"cells":5034},"History of exposure to anti-CD20 treatment since 01\u002F01\u002F2010",{"EARLY_PHASE1":5035,"PHASE1":5037,"PHASE2":5039,"PHASE3":5041,"PHASE4":5043,"NA":5045},{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[],{"trials":5042,"activeCount":100},[],{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[5047],{"nctId":5048,"briefTitle":5049,"status":2074,"phases":5050,"primaryCompletion":5051,"completion":5052,"start":5053,"enrollment":5054,"conditions":5055,"interventions":5058},"NCT04877496","Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.",[],"2021-08-30","2021-10-31","2021-04-26",425,[5056,5057,2035],"COVID19 Vaccination","Rituximab",[5033,5059],"Completion of COVID19 vaccine at least 4 weeks ago",{"intervention":5059,"totalTrials":126,"cells":5061},{"EARLY_PHASE1":5062,"PHASE1":5064,"PHASE2":5066,"PHASE3":5068,"PHASE4":5070,"NA":5072},{"trials":5063,"activeCount":100},[],{"trials":5065,"activeCount":100},[],{"trials":5067,"activeCount":100},[],{"trials":5069,"activeCount":100},[],{"trials":5071,"activeCount":100},[],{"trials":5073,"activeCount":100},[5074],{"nctId":5048,"briefTitle":5049,"status":2074,"phases":5075,"primaryCompletion":5051,"completion":5052,"start":5053,"enrollment":5054,"conditions":5076,"interventions":5077},[],[5056,5057,2035],[5033,5059],{"intervention":5079,"totalTrials":126,"cells":5080},"Intravenous thrombolysis with recombinant tissue-type plasminogen activator",{"EARLY_PHASE1":5081,"PHASE1":5083,"PHASE2":5085,"PHASE3":5087,"PHASE4":5089,"NA":5091},{"trials":5082,"activeCount":100},[],{"trials":5084,"activeCount":100},[],{"trials":5086,"activeCount":100},[],{"trials":5088,"activeCount":100},[],{"trials":5090,"activeCount":100},[],{"trials":5092,"activeCount":100},[5093],{"nctId":5094,"briefTitle":5095,"status":156,"phases":5096,"primaryCompletion":5097,"completion":5098,"start":5099,"enrollment":5100,"conditions":5101,"interventions":5102},"NCT03192332","Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke",[92],"2021-05-14","2021-08-11","2017-11-29",410,[29],[5079],{"intervention":5104,"totalTrials":126,"cells":5105},"Gynoflor",{"EARLY_PHASE1":5106,"PHASE1":5108,"PHASE2":5110,"PHASE3":5112,"PHASE4":5114,"NA":5116},{"trials":5107,"activeCount":100},[],{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":100},[],{"trials":5113,"activeCount":100},[],{"trials":5115,"activeCount":100},[],{"trials":5117,"activeCount":100},[5118],{"nctId":5119,"briefTitle":5120,"status":156,"phases":5121,"primaryCompletion":2250,"completion":5122,"start":5123,"enrollment":2252,"conditions":5124,"interventions":5127},"NCT02887885","Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women",[],"2020-04-10","2018-01-22",[5125,5126],"Atrophy of Vagina","Postmenopause",[5104],{"intervention":5129,"totalTrials":126,"cells":5130},"Influenza vaccine",{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5137,"PHASE4":5139,"NA":5141},{"trials":5132,"activeCount":100},[],{"trials":5134,"activeCount":100},[],{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[],{"trials":5142,"activeCount":100},[5143],{"nctId":5144,"briefTitle":5145,"status":156,"phases":5146,"primaryCompletion":4585,"completion":4585,"start":5147,"enrollment":5148,"conditions":5149,"interventions":5152},"NCT06738082","Influenza Vaccine Elicited Immune Response in Immunocompromised Patients",[],"2024-10-15",147,[5150,5151],"Influenza Vaccine","Immunocompromised Patients",[5129],{"intervention":5154,"totalTrials":126,"cells":5155},"Tisseel®",{"EARLY_PHASE1":5156,"PHASE1":5158,"PHASE2":5160,"PHASE3":5162,"PHASE4":5164,"NA":5166},{"trials":5157,"activeCount":100},[],{"trials":5159,"activeCount":100},[],{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[5168],{"nctId":5169,"briefTitle":5170,"status":2074,"phases":5171,"primaryCompletion":59,"completion":59,"start":2912,"enrollment":5172,"conditions":5173,"interventions":5175},"NCT05490940","Sensory Recovery of Digital Nerves After Microsurgical Epineural Neurorrhaphy Alone or in Combination With Tisseel - RET",[92],74,[5174],"Digital Nerve Injuries",[5154],{"intervention":5177,"totalTrials":126,"cells":5178},"pegfilgrastim",{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5183,"PHASE3":5185,"PHASE4":5187,"NA":5189},{"trials":5180,"activeCount":100},[],{"trials":5182,"activeCount":100},[],{"trials":5184,"activeCount":100},[],{"trials":5186,"activeCount":100},[],{"trials":5188,"activeCount":100},[],{"trials":5190,"activeCount":100},[5191],{"nctId":5192,"briefTitle":5193,"status":156,"phases":5194,"primaryCompletion":5195,"completion":5195,"start":3656,"enrollment":11,"conditions":5196,"interventions":5197},"NCT00886509","Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients",[92],"2015-02",[15],[5177],{"intervention":5199,"totalTrials":126,"cells":5200},"Perindopril",{"EARLY_PHASE1":5201,"PHASE1":5203,"PHASE2":5205,"PHASE3":5207,"PHASE4":5209,"NA":5211},{"trials":5202,"activeCount":100},[],{"trials":5204,"activeCount":100},[],{"trials":5206,"activeCount":100},[],{"trials":5208,"activeCount":100},[],{"trials":5210,"activeCount":100},[],{"trials":5212,"activeCount":100},[5213],{"nctId":5214,"briefTitle":5215,"status":156,"phases":5216,"primaryCompletion":5217,"completion":5218,"start":1423,"enrollment":5219,"conditions":5220,"interventions":5221},"NCT02449811","RAS Peptide Profiles in Patients With Arterial Hypertension",[],"2018-08","2018-11",107,[4564],[5199,5222,5223,5224],"Olmesartan","Amlodipine","Hydrochlorothiazide",{"intervention":5222,"totalTrials":126,"cells":5226},{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5231,"PHASE3":5233,"PHASE4":5235,"NA":5237},{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[],{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[5239],{"nctId":5214,"briefTitle":5215,"status":156,"phases":5240,"primaryCompletion":5217,"completion":5218,"start":1423,"enrollment":5219,"conditions":5241,"interventions":5242},[],[4564],[5199,5222,5223,5224],{"intervention":5223,"totalTrials":126,"cells":5244},{"EARLY_PHASE1":5245,"PHASE1":5247,"PHASE2":5249,"PHASE3":5251,"PHASE4":5253,"NA":5255},{"trials":5246,"activeCount":100},[],{"trials":5248,"activeCount":100},[],{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[5257],{"nctId":5214,"briefTitle":5215,"status":156,"phases":5258,"primaryCompletion":5217,"completion":5218,"start":1423,"enrollment":5219,"conditions":5259,"interventions":5260},[],[4564],[5199,5222,5223,5224],{"intervention":5224,"totalTrials":126,"cells":5262},{"EARLY_PHASE1":5263,"PHASE1":5265,"PHASE2":5267,"PHASE3":5269,"PHASE4":5271,"NA":5273},{"trials":5264,"activeCount":100},[],{"trials":5266,"activeCount":100},[],{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[5275],{"nctId":5214,"briefTitle":5215,"status":156,"phases":5276,"primaryCompletion":5217,"completion":5218,"start":1423,"enrollment":5219,"conditions":5277,"interventions":5278},[],[4564],[5199,5222,5223,5224],{"intervention":5280,"totalTrials":126,"cells":5281},"Sampling at baseline, one week after baseline, two weeks after baseline",{"EARLY_PHASE1":5282,"PHASE1":5284,"PHASE2":5286,"PHASE3":5288,"PHASE4":5290,"NA":5292},{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[],{"trials":5287,"activeCount":100},[],{"trials":5289,"activeCount":100},[],{"trials":5291,"activeCount":100},[],{"trials":5293,"activeCount":100},[5294],{"nctId":5295,"briefTitle":5296,"status":156,"phases":5297,"primaryCompletion":5298,"completion":5298,"start":5299,"enrollment":4515,"conditions":5300,"interventions":5302},"NCT01975558","The Radiation Metabolic Signature of Patient Undergoing Radiotherapy. A Pilot Study",[],"2019-11-12","2014-06-26",[5301],"Breast Cancer",[5280,5303],"Sampling at baseline, during radiotherapy and after",{"intervention":5303,"totalTrials":126,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5312,"PHASE4":5314,"NA":5316},{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[],{"trials":5311,"activeCount":100},[],{"trials":5313,"activeCount":100},[],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[5318],{"nctId":5295,"briefTitle":5296,"status":156,"phases":5319,"primaryCompletion":5298,"completion":5298,"start":5299,"enrollment":4515,"conditions":5320,"interventions":5321},[],[5301],[5280,5303],{"intervention":5323,"totalTrials":126,"cells":5324},"Inhaled nitric oxide",{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5331,"PHASE4":5333,"NA":5335},{"trials":5326,"activeCount":100},[],{"trials":5328,"activeCount":100},[],{"trials":5330,"activeCount":100},[],{"trials":5332,"activeCount":100},[],{"trials":5334,"activeCount":100},[],{"trials":5336,"activeCount":100},[5337],{"nctId":5338,"briefTitle":5339,"status":156,"phases":5340,"primaryCompletion":5341,"completion":5342,"start":5343,"enrollment":1789,"conditions":5344,"interventions":5349},"NCT04988932","Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm",[92],"2019-07-28","2020-03-20","2012-07-31",[5345,5346,5347,5348],"SAH","Inhaled Nitric Oxide","Cerebral Ischemia","Vasospasm",[5323],{"intervention":5351,"totalTrials":126,"cells":5352},"Antithrombotic treatment",{"EARLY_PHASE1":5353,"PHASE1":5355,"PHASE2":5357,"PHASE3":5359,"PHASE4":5361,"NA":5363},{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[],{"trials":5362,"activeCount":100},[],{"trials":5364,"activeCount":100},[5365],{"nctId":5366,"briefTitle":5367,"status":2074,"phases":5368,"primaryCompletion":3043,"completion":3043,"start":5369,"enrollment":5370,"conditions":5371,"interventions":5373},"NCT00859885","International PFO Consortium",[],"2008-09-08",1500,[21,5372],"Transient Ischemic Attack",[5351],{"intervention":5375,"totalTrials":126,"cells":5376},"metagenome",{"EARLY_PHASE1":5377,"PHASE1":5379,"PHASE2":5381,"PHASE3":5383,"PHASE4":5385,"NA":5387},{"trials":5378,"activeCount":100},[],{"trials":5380,"activeCount":100},[],{"trials":5382,"activeCount":100},[],{"trials":5384,"activeCount":100},[],{"trials":5386,"activeCount":100},[],{"trials":5388,"activeCount":100},[5389],{"nctId":5390,"briefTitle":5391,"status":2074,"phases":5392,"primaryCompletion":4342,"completion":4342,"start":5393,"enrollment":5394,"conditions":5395,"interventions":5396},"NCT02438111","The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)",[],"2013-12",1200,[2157],[5375],{"intervention":4283,"totalTrials":126,"cells":5398},{"EARLY_PHASE1":5399,"PHASE1":5401,"PHASE2":5403,"PHASE3":5405,"PHASE4":5407,"NA":5409},{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[],{"trials":5408,"activeCount":100},[],{"trials":5410,"activeCount":100},[5411],{"nctId":4273,"briefTitle":4274,"status":156,"phases":5412,"primaryCompletion":4276,"completion":4276,"start":4277,"enrollment":25,"conditions":5413,"interventions":5414},[92],[4279,4280,4281],[164,4258,4283],{"intervention":5416,"totalTrials":126,"cells":5417},"azithromycin",{"EARLY_PHASE1":5418,"PHASE1":5420,"PHASE2":5422,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5419,"activeCount":100},[],{"trials":5421,"activeCount":100},[],{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[5430],{"nctId":5431,"briefTitle":5432,"status":156,"phases":5433,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":5436,"conditions":5437,"interventions":5440},"NCT02173145","Azithromycin in Idiopathic Pulmonary Fibrosis",[92],"2019-08-16","2014-08-19",27,[5438,5439],"Idiopathic Pulmonary Fibrosis","Cough",[5416],{"intervention":5442,"totalTrials":126,"cells":5443},"Aflibercept",{"EARLY_PHASE1":5444,"PHASE1":5446,"PHASE2":5448,"PHASE3":5450,"PHASE4":5452,"NA":5454},{"trials":5445,"activeCount":100},[],{"trials":5447,"activeCount":100},[],{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"trials":5453,"activeCount":100},[],{"trials":5455,"activeCount":100},[5456],{"nctId":5457,"briefTitle":5458,"status":156,"phases":5459,"primaryCompletion":5460,"completion":5461,"start":1424,"enrollment":1426,"conditions":5462,"interventions":5463},"NCT02550002","Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen",[],"2022-03","2022-08",[2157],[5442]]